Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
Identifieur interne : 000015 ( Pmc/Corpus ); précédent : 000014; suivant : 000016Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
Auteurs : Mazen Kreidy ; Ali Al-Hilli ; Ralph Yachoui ; Jeffrey ResnickSource :
- BMC Pulmonary Medicine [ 1471-2466 ] ; 2020.
Abstract
Scleromyxedema is a progressive, systemic connective tissue disorder characterized by fibro-mucous skin lesions and increased serum monoclonal immunoglobulin levels. Pulmonary involvement occurs in a subset of patients, though the overall prevalence of pulmonary lesions in scleromyxedema is unknown. Since pulmonary hypertension presumably occurs in these patients due to disease progression and development of additional conditions, treatment of the underlying plasma cell dyscrasia and connective tissue disorder may improve pulmonary hypertension symptoms.
An elderly patient with scleromyxedema developed pulmonary hypertension refractory to vasodilator and diuretic therapy and subsequently multiple myeloma that responded to a combination therapy of bortezomib, cyclophosphamide, and dexamethasone treatment.
Treatment of the underlying disease(s) that contributed to pulmonary hypertension development with anti-neoplastic agents like bortezomib may improve cardiopulmonary symptoms secondary to reducing abnormal blood cell counts and paraprotein levels.
Url:
DOI: 10.1186/s12890-019-1020-6
PubMed: 31918690
PubMed Central: 6953266
Links to Exploration step
PMC:6953266Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report</title><author><name sortKey="Kreidy, Mazen" sort="Kreidy, Mazen" uniqKey="Kreidy M" first="Mazen" last="Kreidy">Mazen Kreidy</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Pulmonary and Critical Care Medicine,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</nlm:aff></affiliation><affiliation><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0444 1241</institution-id><institution-id institution-id-type="GRID">grid.414316.5</institution-id><institution>Present affiliation: Christiana Care Health System,</institution></institution-wrap>PO Box 1668, Wilmington, DE 19899 USA</nlm:aff></affiliation></author><author><name sortKey="Al Hilli, Ali" sort="Al Hilli, Ali" uniqKey="Al Hilli A" first="Ali" last="Al-Hilli">Ali Al-Hilli</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Internal Medicine,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</nlm:aff></affiliation></author><author><name sortKey="Yachoui, Ralph" sort="Yachoui, Ralph" uniqKey="Yachoui R" first="Ralph" last="Yachoui">Ralph Yachoui</name><affiliation><nlm:aff id="Aff3">Department of Rheumatology, Ronald Reagan UCLA Medical Center, Santa Monica, California, USA</nlm:aff></affiliation></author><author><name sortKey="Resnick, Jeffrey" sort="Resnick, Jeffrey" uniqKey="Resnick J" first="Jeffrey" last="Resnick">Jeffrey Resnick</name><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Pathology,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31918690</idno><idno type="pmc">6953266</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953266</idno><idno type="RBID">PMC:6953266</idno><idno type="doi">10.1186/s12890-019-1020-6</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000015</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000015</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report</title><author><name sortKey="Kreidy, Mazen" sort="Kreidy, Mazen" uniqKey="Kreidy M" first="Mazen" last="Kreidy">Mazen Kreidy</name><affiliation><nlm:aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Pulmonary and Critical Care Medicine,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</nlm:aff></affiliation><affiliation><nlm:aff id="Aff5"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0444 1241</institution-id><institution-id institution-id-type="GRID">grid.414316.5</institution-id><institution>Present affiliation: Christiana Care Health System,</institution></institution-wrap>PO Box 1668, Wilmington, DE 19899 USA</nlm:aff></affiliation></author><author><name sortKey="Al Hilli, Ali" sort="Al Hilli, Ali" uniqKey="Al Hilli A" first="Ali" last="Al-Hilli">Ali Al-Hilli</name><affiliation><nlm:aff id="Aff2"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Internal Medicine,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</nlm:aff></affiliation></author><author><name sortKey="Yachoui, Ralph" sort="Yachoui, Ralph" uniqKey="Yachoui R" first="Ralph" last="Yachoui">Ralph Yachoui</name><affiliation><nlm:aff id="Aff3">Department of Rheumatology, Ronald Reagan UCLA Medical Center, Santa Monica, California, USA</nlm:aff></affiliation></author><author><name sortKey="Resnick, Jeffrey" sort="Resnick, Jeffrey" uniqKey="Resnick J" first="Jeffrey" last="Resnick">Jeffrey Resnick</name><affiliation><nlm:aff id="Aff4"><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Pathology,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</nlm:aff></affiliation></author></analytic><series><title level="j">BMC Pulmonary Medicine</title><idno type="eISSN">1471-2466</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p id="Par1">Scleromyxedema is a progressive, systemic connective tissue disorder characterized by fibro-mucous skin lesions and increased serum monoclonal immunoglobulin levels. Pulmonary involvement occurs in a subset of patients, though the overall prevalence of pulmonary lesions in scleromyxedema is unknown. Since pulmonary hypertension presumably occurs in these patients due to disease progression and development of additional conditions, treatment of the underlying plasma cell dyscrasia and connective tissue disorder may improve pulmonary hypertension symptoms.</p></sec><sec><title>Case presentation</title><p id="Par2">An elderly patient with scleromyxedema developed pulmonary hypertension refractory to vasodilator and diuretic therapy and subsequently multiple myeloma that responded to a combination therapy of bortezomib, cyclophosphamide, and dexamethasone treatment.</p></sec><sec><title>Conclusions</title><p id="Par3">Treatment of the underlying disease(s) that contributed to pulmonary hypertension development with anti-neoplastic agents like bortezomib may improve cardiopulmonary symptoms secondary to reducing abnormal blood cell counts and paraprotein levels.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Mccarthy, Jt" uniqKey="Mccarthy J">JT McCarthy</name></author><author><name sortKey="Osserman, E" uniqKey="Osserman E">E Osserman</name></author><author><name sortKey="Lombardo, Pc" uniqKey="Lombardo P">PC Lombardo</name></author><author><name sortKey="Takatsuki, K" uniqKey="Takatsuki K">K Takatsuki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gabriel, Se" uniqKey="Gabriel S">SE Gabriel</name></author><author><name sortKey="Perry, Ho" uniqKey="Perry H">HO Perry</name></author><author><name sortKey="Oleson, Gb" uniqKey="Oleson G">GB Oleson</name></author><author><name sortKey="Bowles, Ca" uniqKey="Bowles C">CA Bowles</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dinneen, Am" uniqKey="Dinneen A">AM Dinneen</name></author><author><name sortKey="Dicken, Ch" uniqKey="Dicken C">CH Dicken</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Blum, M" uniqKey="Blum M">M Blum</name></author><author><name sortKey="Wigley, Fm" uniqKey="Wigley F">FM Wigley</name></author><author><name sortKey="Hummers, Lk" uniqKey="Hummers L">LK Hummers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rongioletti, F" uniqKey="Rongioletti F">F Rongioletti</name></author><author><name sortKey="Merlo, G" uniqKey="Merlo G">G Merlo</name></author><author><name sortKey="Cinotti, E" uniqKey="Cinotti E">E Cinotti</name></author><author><name sortKey="Fausti, V" uniqKey="Fausti V">V Fausti</name></author><author><name sortKey="Cozzani, E" uniqKey="Cozzani E">E Cozzani</name></author><author><name sortKey="Cribier, B" uniqKey="Cribier B">B Cribier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rongioletti, F" uniqKey="Rongioletti F">F Rongioletti</name></author><author><name sortKey="Merlo, G" uniqKey="Merlo G">G Merlo</name></author><author><name sortKey="Carli, C" uniqKey="Carli C">C Carli</name></author><author><name sortKey="Cribier, B" uniqKey="Cribier B">B Cribier</name></author><author><name sortKey="Metze, D" uniqKey="Metze D">D Metze</name></author><author><name sortKey="Calonje, E" uniqKey="Calonje E">E Calonje</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Ferreli, C" uniqKey="Ferreli C">C Ferreli</name></author><author><name sortKey="Gasparini, G" uniqKey="Gasparini G">G Gasparini</name></author><author><name sortKey="Parodi, A" uniqKey="Parodi A">A Parodi</name></author><author><name sortKey="Cozzani, E" uniqKey="Cozzani E">E Cozzani</name></author><author><name sortKey="Rongioletti, F" uniqKey="Rongioletti F">F Rongioletti</name></author><author><name sortKey="Atzori, L" uniqKey="Atzori L">L Atzori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Knobler, R" uniqKey="Knobler R">R Knobler</name></author><author><name sortKey="Moinzadeh, P" uniqKey="Moinzadeh P">P Moinzadeh</name></author><author><name sortKey="Hunzelmann, N" uniqKey="Hunzelmann N">N Hunzelmann</name></author><author><name sortKey="Kreuter, A" uniqKey="Kreuter A">A Kreuter</name></author><author><name sortKey="Cozzio, A" uniqKey="Cozzio A">A Cozzio</name></author><author><name sortKey="Mouthon, L" uniqKey="Mouthon L">L Mouthon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rongioletti, F" uniqKey="Rongioletti F">F Rongioletti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alberts, As" uniqKey="Alberts A">AS Alberts</name></author><author><name sortKey="Schulz, Ej" uniqKey="Schulz E">EJ Schulz</name></author><author><name sortKey="Falkson, G" uniqKey="Falkson G">G Falkson</name></author><author><name sortKey="Simson, Iw" uniqKey="Simson I">IW Simson</name></author><author><name sortKey="Coccia Portugal, Ma" uniqKey="Coccia Portugal M">MA Coccia-Portugal</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gimenez Garcia, R" uniqKey="Gimenez Garcia R">R Giménez Garcia</name></author><author><name sortKey="Garcia, Sg" uniqKey="Garcia S">SG Garcia</name></author><author><name sortKey="Suarez Vilela, D" uniqKey="Suarez Vilela D">D Suarez Vilela</name></author><author><name sortKey="Moro Sanchez, Mj" uniqKey="Moro Sanchez M">MJ Moro Sanchez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Godby, A" uniqKey="Godby A">A Godby</name></author><author><name sortKey="Bergstresser, Pr" uniqKey="Bergstresser P">PR Bergstresser</name></author><author><name sortKey="Chaker, B" uniqKey="Chaker B">B Chaker</name></author><author><name sortKey="Pandya, Ag" uniqKey="Pandya A">AG Pandya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Loggini, B" uniqKey="Loggini B">B Loggini</name></author><author><name sortKey="Pingitore, R" uniqKey="Pingitore R">R Pingitore</name></author><author><name sortKey="Avvenente, A" uniqKey="Avvenente A">A Avvenente</name></author><author><name sortKey="Giuliano, G" uniqKey="Giuliano G">G Giuliano</name></author><author><name sortKey="Barachini, P" uniqKey="Barachini P">P Barachini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Simone, C" uniqKey="De Simone C">C De Simone</name></author><author><name sortKey="Castriota, M" uniqKey="Castriota M">M Castriota</name></author><author><name sortKey="Carbone, A" uniqKey="Carbone A">A Carbone</name></author><author><name sortKey="Marini Bettolo, P" uniqKey="Marini Bettolo P">P Marini Bettolo</name></author><author><name sortKey="Pieroni, M" uniqKey="Pieroni M">M Pieroni</name></author><author><name sortKey="Rongioletti, F" uniqKey="Rongioletti F">F Rongioletti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fett, Nm" uniqKey="Fett N">NM Fett</name></author><author><name sortKey="Toporcer, Mb" uniqKey="Toporcer M">MB Toporcer</name></author><author><name sortKey="Dalmau, J" uniqKey="Dalmau J">J Dalmau</name></author><author><name sortKey="Shinohara, Mm" uniqKey="Shinohara M">MM Shinohara</name></author><author><name sortKey="Vogl, Dt" uniqKey="Vogl D">DT Vogl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sala, Ac" uniqKey="Sala A">AC Sala</name></author><author><name sortKey="Cunha, Pr" uniqKey="Cunha P">PR Cunha</name></author><author><name sortKey="Pinto, Ca" uniqKey="Pinto C">CA Pinto</name></author><author><name sortKey="Alves, Ca" uniqKey="Alves C">CA Alves</name></author><author><name sortKey="Paiva, Ib" uniqKey="Paiva I">IB Paiva</name></author><author><name sortKey="Araujo, Ap" uniqKey="Araujo A">AP Araujo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Muldrow, Ml" uniqKey="Muldrow M">ML Muldrow</name></author><author><name sortKey="Bailin, Pl" uniqKey="Bailin P">PL Bailin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yeung, Ck" uniqKey="Yeung C">CK Yeung</name></author><author><name sortKey="Loong, F" uniqKey="Loong F">F Loong</name></author><author><name sortKey="Kwong, Yl" uniqKey="Kwong Y">YL Kwong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bos, R" uniqKey="Bos R">R Bos</name></author><author><name sortKey="De Waal, Eg" uniqKey="De Waal E">EG de Waal</name></author><author><name sortKey="Kuiper, H" uniqKey="Kuiper H">H Kuiper</name></author><author><name sortKey="Hazenberg, Bp" uniqKey="Hazenberg B">BP Hazenberg</name></author><author><name sortKey="Vellenga, E" uniqKey="Vellenga E">E Vellenga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ca Ueto, J" uniqKey="Ca Ueto J">J Cañueto</name></author><author><name sortKey="Labrador, J" uniqKey="Labrador J">J Labrador</name></author><author><name sortKey="Roman, C" uniqKey="Roman C">C Román</name></author><author><name sortKey="Santos Briz, A" uniqKey="Santos Briz A">A Santos-Briz</name></author><author><name sortKey="Contreras, T" uniqKey="Contreras T">T Contreras</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Migkou, M" uniqKey="Migkou M">M Migkou</name></author><author><name sortKey="Gkotzamanidou, M" uniqKey="Gkotzamanidou M">M Gkotzamanidou</name></author><author><name sortKey="Terpos, E" uniqKey="Terpos E">E Terpos</name></author><author><name sortKey="Dimopoulos, Ma" uniqKey="Dimopoulos M">MA Dimopoulos</name></author><author><name sortKey="Kastritis, E" uniqKey="Kastritis E">E Kastritis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yaqub, S" uniqKey="Yaqub S">S Yaqub</name></author><author><name sortKey="Moder, Kg" uniqKey="Moder K">KG Moder</name></author><author><name sortKey="Lacy, Mq" uniqKey="Lacy M">MQ Lacy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feyereisn, Wl" uniqKey="Feyereisn W">WL Feyereisn</name></author><author><name sortKey="Fenstad, Er" uniqKey="Fenstad E">ER Fenstad</name></author><author><name sortKey="Mccully, Rb" uniqKey="Mccully R">RB McCully</name></author><author><name sortKey="Lacy, Mq" uniqKey="Lacy M">MQ Lacy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rather, Pa" uniqKey="Rather P">PA Rather</name></author><author><name sortKey="Hussain, M" uniqKey="Hussain M">M Hussain</name></author><author><name sortKey="Bagdadi, F" uniqKey="Bagdadi F">F Bagdadi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Truhan, Ap" uniqKey="Truhan A">AP Truhan</name></author><author><name sortKey="Roenigk, Hh" uniqKey="Roenigk H">HH Roenigk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuldeep, Cm" uniqKey="Kuldeep C">CM Kuldeep</name></author><author><name sortKey="Mittal, Ak" uniqKey="Mittal A">AK Mittal</name></author><author><name sortKey="Gupta, Lk" uniqKey="Gupta L">LK Gupta</name></author><author><name sortKey="Paliwal, Vk" uniqKey="Paliwal V">VK Paliwal</name></author><author><name sortKey="Sharma, P" uniqKey="Sharma P">P Sharma</name></author><author><name sortKey="Garg, A" uniqKey="Garg A">A Garg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feasel, Am" uniqKey="Feasel A">AM Feasel</name></author><author><name sortKey="Donato, Ml" uniqKey="Donato M">ML Donato</name></author><author><name sortKey="Duvic, M" uniqKey="Duvic M">M Duvic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ataergin, S" uniqKey="Ataergin S">S Ataergin</name></author><author><name sortKey="Arpaci, F" uniqKey="Arpaci F">F Arpaci</name></author><author><name sortKey="Demiriz, M" uniqKey="Demiriz M">M Demiriz</name></author><author><name sortKey="Ozet, A" uniqKey="Ozet A">A Ozet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rayson, D" uniqKey="Rayson D">D Rayson</name></author><author><name sortKey="Lust, Ja" uniqKey="Lust J">JA Lust</name></author><author><name sortKey="Duncan, A" uniqKey="Duncan A">A Duncan</name></author><author><name sortKey="Su, Wp" uniqKey="Su W">WP Su</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wright, Rc" uniqKey="Wright R">RC Wright</name></author><author><name sortKey="Franco, Rs" uniqKey="Franco R">RS Franco</name></author><author><name sortKey="Denton, D" uniqKey="Denton D">D Denton</name></author><author><name sortKey="Blaney, Dj" uniqKey="Blaney D">DJ Blaney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, Yc" uniqKey="Lin Y">YC Lin</name></author><author><name sortKey="Wang, Hc" uniqKey="Wang H">HC Wang</name></author><author><name sortKey="Shen, Jl" uniqKey="Shen J">JL Shen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kreuter, A" uniqKey="Kreuter A">A Kreuter</name></author><author><name sortKey="Altmeyer, P" uniqKey="Altmeyer P">P Altmeyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Horn, Kb" uniqKey="Horn K">KB Horn</name></author><author><name sortKey="Horn, Ma" uniqKey="Horn M">MA Horn</name></author><author><name sortKey="Swan, J" uniqKey="Swan J">J Swan</name></author><author><name sortKey="Singhal, S" uniqKey="Singhal S">S Singhal</name></author><author><name sortKey="Guitart, J" uniqKey="Guitart J">J Guitart</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lacy, Mq" uniqKey="Lacy M">MQ Lacy</name></author><author><name sortKey="Hogan, Wj" uniqKey="Hogan W">WJ Hogan</name></author><author><name sortKey="Gertz, Ma" uniqKey="Gertz M">MA Gertz</name></author><author><name sortKey="Dispenzieri, A" uniqKey="Dispenzieri A">A Dispenzieri</name></author><author><name sortKey="Rajkumar, Sv" uniqKey="Rajkumar S">SV Rajkumar</name></author><author><name sortKey="Hayman, S" uniqKey="Hayman S">S Hayman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Macfarlane, Aw" uniqKey="Macfarlane A">AW MacFarlane</name></author><author><name sortKey="Davenport, A" uniqKey="Davenport A">A Davenport</name></author><author><name sortKey="Verbov, Jl" uniqKey="Verbov J">JL Verbov</name></author><author><name sortKey="Goldsmith, Hj" uniqKey="Goldsmith H">HJ Goldsmith</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keong, Ch" uniqKey="Keong C">CH Keong</name></author><author><name sortKey="Asaka, Y" uniqKey="Asaka Y">Y Asaka</name></author><author><name sortKey="Fukuro, S" uniqKey="Fukuro S">S Fukuro</name></author><author><name sortKey="Miyamoto, C" uniqKey="Miyamoto C">C Miyamoto</name></author><author><name sortKey="Katsumata, M" uniqKey="Katsumata M">M Katsumata</name></author><author><name sortKey="Iino, Y" uniqKey="Iino Y">Y Iino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hill, Tg" uniqKey="Hill T">TG Hill</name></author><author><name sortKey="Crawford, Jn" uniqKey="Crawford J">JN Crawford</name></author><author><name sortKey="Rogers, Cc" uniqKey="Rogers C">CC Rogers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morris Jones, R" uniqKey="Morris Jones R">R Morris-Jones</name></author><author><name sortKey="Staughton, Rc" uniqKey="Staughton R">RC Staughton</name></author><author><name sortKey="Walker, M" uniqKey="Walker M">M Walker</name></author><author><name sortKey="Sheridan, Dj" uniqKey="Sheridan D">DJ Sheridan</name></author><author><name sortKey="Rajappan, K" uniqKey="Rajappan K">K Rajappan</name></author><author><name sortKey="Leonard, J" uniqKey="Leonard J">J Leonard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bidier, M" uniqKey="Bidier M">M Bidier</name></author><author><name sortKey="Zschoche, C" uniqKey="Zschoche C">C Zschoche</name></author><author><name sortKey="Gholam, P" uniqKey="Gholam P">P Gholam</name></author><author><name sortKey="Enk, Ah" uniqKey="Enk A">AH Enk</name></author><author><name sortKey="Hadaschik, En" uniqKey="Hadaschik E">EN Hadaschik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Galie, N" uniqKey="Galie N">N Galiè</name></author><author><name sortKey="Humbert, M" uniqKey="Humbert M">M Humbert</name></author><author><name sortKey="Vachiery, Jl" uniqKey="Vachiery J">JL Vachiery</name></author><author><name sortKey="Gibbs, S" uniqKey="Gibbs S">S Gibbs</name></author><author><name sortKey="Lang, I" uniqKey="Lang I">I Lang</name></author><author><name sortKey="Torbicki, A" uniqKey="Torbicki A">A Torbicki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Marvin, Ks" uniqKey="Marvin K">KS Marvin</name></author><author><name sortKey="Spellberg, Rd" uniqKey="Spellberg R">RD Spellberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nand, S" uniqKey="Nand S">S Nand</name></author><author><name sortKey="Orfei, E" uniqKey="Orfei E">E Orfei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rossoff, Lj" uniqKey="Rossoff L">LJ Rossoff</name></author><author><name sortKey="Genovese, J" uniqKey="Genovese J">J Genovese</name></author><author><name sortKey="Coleman, M" uniqKey="Coleman M">M Coleman</name></author><author><name sortKey="Dantzker, Dr" uniqKey="Dantzker D">DR Dantzker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Garcia Manero, G" uniqKey="Garcia Manero G">G García-Manero</name></author><author><name sortKey="Schuster, Sj" uniqKey="Schuster S">SJ Schuster</name></author><author><name sortKey="Patrick, H" uniqKey="Patrick H">H Patrick</name></author><author><name sortKey="Martinez, J" uniqKey="Martinez J">J Martinez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dingli, D" uniqKey="Dingli D">D Dingli</name></author><author><name sortKey="Utz, Jp" uniqKey="Utz J">JP Utz</name></author><author><name sortKey="Krowka, Mj" uniqKey="Krowka M">MJ Krowka</name></author><author><name sortKey="Oberg, Al" uniqKey="Oberg A">AL Oberg</name></author><author><name sortKey="Tefferi, A" uniqKey="Tefferi A">A Tefferi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steensma, Dp" uniqKey="Steensma D">DP Steensma</name></author><author><name sortKey="Hook, Cc" uniqKey="Hook C">CC Hook</name></author><author><name sortKey="Stafford, Sl" uniqKey="Stafford S">SL Stafford</name></author><author><name sortKey="Tefferi, A" uniqKey="Tefferi A">A Tefferi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Popat, U" uniqKey="Popat U">U Popat</name></author><author><name sortKey="Frost, A" uniqKey="Frost A">A Frost</name></author><author><name sortKey="Liu, E" uniqKey="Liu E">E Liu</name></author><author><name sortKey="May, R" uniqKey="May R">R May</name></author><author><name sortKey="Bag, R" uniqKey="Bag R">R Bag</name></author><author><name sortKey="Reddy, V" uniqKey="Reddy V">V Reddy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rostagno, C" uniqKey="Rostagno C">C Rostagno</name></author><author><name sortKey="Ciolli, S" uniqKey="Ciolli S">S Ciolli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cortelezzi, A" uniqKey="Cortelezzi A">A Cortelezzi</name></author><author><name sortKey="Gritti, G" uniqKey="Gritti G">G Gritti</name></author><author><name sortKey="Del Papa, N" uniqKey="Del Papa N">N Del Papa</name></author><author><name sortKey="Pasquini, Mc" uniqKey="Pasquini M">MC Pasquini</name></author><author><name sortKey="Calori, R" uniqKey="Calori R">R Calori</name></author><author><name sortKey="Gianelli, U" uniqKey="Gianelli U">U Gianelli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Willems, E" uniqKey="Willems E">E Willems</name></author><author><name sortKey="Canivet, Jl" uniqKey="Canivet J">JL Canivet</name></author><author><name sortKey="Ghaye, B" uniqKey="Ghaye B">B Ghaye</name></author><author><name sortKey="De Leval, L" uniqKey="De Leval L">L de Leval</name></author><author><name sortKey="Radermecker, M" uniqKey="Radermecker M">M Radermecker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adir, Y" uniqKey="Adir Y">Y Adir</name></author><author><name sortKey="Elia, D" uniqKey="Elia D">D Elia</name></author><author><name sortKey="Harari, S" uniqKey="Harari S">S Harari</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Krishnan, U" uniqKey="Krishnan U">U Krishnan</name></author><author><name sortKey="Mark, Tm" uniqKey="Mark T">TM Mark</name></author><author><name sortKey="Niesvizky, R" uniqKey="Niesvizky R">R Niesvizky</name></author><author><name sortKey="Sobol, I" uniqKey="Sobol I">I Sobol</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roach, Ec" uniqKey="Roach E">EC Roach</name></author><author><name sortKey="Park, Mm" uniqKey="Park M">MM Park</name></author><author><name sortKey="Tang, Wh" uniqKey="Tang W">WH Tang</name></author><author><name sortKey="Thomas, Jd" uniqKey="Thomas J">JD Thomas</name></author><author><name sortKey="Asosingh, K" uniqKey="Asosingh K">K Asosingh</name></author><author><name sortKey="Kalaycio, M" uniqKey="Kalaycio M">M Kalaycio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mattar, Mervat M" uniqKey="Mattar M">Mervat M. Mattar</name></author><author><name sortKey="Morad, Mohammed Abdel Kader" uniqKey="Morad M">Mohammed Abdel Kader Morad</name></author><author><name sortKey="El Husseiny, Noha M" uniqKey="El Husseiny N">Noha M. El Husseiny</name></author><author><name sortKey="Ali, Noha H" uniqKey="Ali N">Noha H. Ali</name></author><author><name sortKey="El Demerdash, Doaa M" uniqKey="El Demerdash D">Doaa M. El Demerdash</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Montani, D" uniqKey="Montani D">D Montani</name></author><author><name sortKey="Achouh, L" uniqKey="Achouh L">L Achouh</name></author><author><name sortKey="Marcelin, Ag" uniqKey="Marcelin A">AG Marcelin</name></author><author><name sortKey="Viard, Jp" uniqKey="Viard J">JP Viard</name></author><author><name sortKey="Hermine, O" uniqKey="Hermine O">O Hermine</name></author><author><name sortKey="Canioni, D" uniqKey="Canioni D">D Canioni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taytawat, P" uniqKey="Taytawat P">P Taytawat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tamura, S" uniqKey="Tamura S">S Tamura</name></author><author><name sortKey="Koyama, A" uniqKey="Koyama A">A Koyama</name></author><author><name sortKey="Shiotani, C" uniqKey="Shiotani C">C Shiotani</name></author><author><name sortKey="Kurihara, T" uniqKey="Kurihara T">T Kurihara</name></author><author><name sortKey="Nishikawa, A" uniqKey="Nishikawa A">A Nishikawa</name></author><author><name sortKey="Okamoto, Y" uniqKey="Okamoto Y">Y Okamoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Warsame, R" uniqKey="Warsame R">R Warsame</name></author><author><name sortKey="Kohut, Ie" uniqKey="Kohut I">IE Kohut</name></author><author><name sortKey="Dispenzieri, A" uniqKey="Dispenzieri A">A Dispenzieri</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Adam, Z" uniqKey="Adam Z">Z Adam</name></author><author><name sortKey="Krej, M" uniqKey="Krej M">M Krejčí</name></author><author><name sortKey="Pour, L" uniqKey="Pour L">L Pour</name></author><author><name sortKey="Feit, J" uniqKey="Feit J">J Feit</name></author><author><name sortKey="Buchler, T" uniqKey="Buchler T">T Büchler</name></author><author><name sortKey="Hajek, R" uniqKey="Hajek R">R Hájek</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Fox, A" uniqKey="Fox A">A Fox</name></author><author><name sortKey="Farr, G" uniqKey="Farr G">G Farr</name></author><author><name sortKey="Grinnan, D" uniqKey="Grinnan D">D Grinnan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Miyakoshi, S" uniqKey="Miyakoshi S">S Miyakoshi</name></author><author><name sortKey="Kami, M" uniqKey="Kami M">M Kami</name></author><author><name sortKey="Yuji, K" uniqKey="Yuji K">K Yuji</name></author><author><name sortKey="Matsumura, T" uniqKey="Matsumura T">T Matsumura</name></author><author><name sortKey="Takatoku, M" uniqKey="Takatoku M">M Takatoku</name></author><author><name sortKey="Sasaki, M" uniqKey="Sasaki M">M Sasaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boyer, Je" uniqKey="Boyer J">JE Boyer</name></author><author><name sortKey="Batra, Rb" uniqKey="Batra R">RB Batra</name></author><author><name sortKey="Ascensao, Jl" uniqKey="Ascensao J">JL Ascensao</name></author><author><name sortKey="Schechter, Gp" uniqKey="Schechter G">GP Schechter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gotoh, A" uniqKey="Gotoh A">A Gotoh</name></author><author><name sortKey="Ohyashiki, K" uniqKey="Ohyashiki K">K Ohyashiki</name></author><author><name sortKey="Oshimi, K" uniqKey="Oshimi K">K Oshimi</name></author><author><name sortKey="Usui, N" uniqKey="Usui N">N Usui</name></author><author><name sortKey="Hotta, T" uniqKey="Hotta T">T Hotta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ohri, A" uniqKey="Ohri A">A Ohri</name></author><author><name sortKey="Arena, Fp" uniqKey="Arena F">FP Arena</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chew, E" uniqKey="Chew E">E Chew</name></author><author><name sortKey="Filshie, R" uniqKey="Filshie R">R Filshie</name></author><author><name sortKey="Wei, A" uniqKey="Wei A">A Wei</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Duek, A" uniqKey="Duek A">A Duek</name></author><author><name sortKey="Feldberg, E" uniqKey="Feldberg E">E Feldberg</name></author><author><name sortKey="Haran, M" uniqKey="Haran M">M Haran</name></author><author><name sortKey="Berrebi, A" uniqKey="Berrebi A">A Berrebi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pitini, V" uniqKey="Pitini V">V Pitini</name></author><author><name sortKey="Arrigo, C" uniqKey="Arrigo C">C Arrigo</name></author><author><name sortKey="Altavilla, G" uniqKey="Altavilla G">G Altavilla</name></author><author><name sortKey="Naro, C" uniqKey="Naro C">C Naro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zappasodi, P" uniqKey="Zappasodi P">P Zappasodi</name></author><author><name sortKey="Dore, R" uniqKey="Dore R">R Dore</name></author><author><name sortKey="Castagnola, C" uniqKey="Castagnola C">C Castagnola</name></author><author><name sortKey="Astori, C" uniqKey="Astori C">C Astori</name></author><author><name sortKey="Varettoni, M" uniqKey="Varettoni M">M Varettoni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lafaras, C" uniqKey="Lafaras C">C Lafaras</name></author><author><name sortKey="Mandala, E" uniqKey="Mandala E">E Mandala</name></author><author><name sortKey="Verrou, E" uniqKey="Verrou E">E Verrou</name></author><author><name sortKey="Platogiannis, D" uniqKey="Platogiannis D">D Platogiannis</name></author><author><name sortKey="Barbetakis, N" uniqKey="Barbetakis N">N Barbetakis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghose, A" uniqKey="Ghose A">A Ghose</name></author><author><name sortKey="Tariq, Z" uniqKey="Tariq Z">Z Tariq</name></author><author><name sortKey="Taj, A" uniqKey="Taj A">A Taj</name></author><author><name sortKey="Chaudhary, R" uniqKey="Chaudhary R">R Chaudhary</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Montani, D" uniqKey="Montani D">D Montani</name></author><author><name sortKey="Bergot, E" uniqKey="Bergot E">E Bergot</name></author><author><name sortKey="Gunther, S" uniqKey="Gunther S">S Günther</name></author><author><name sortKey="Savale, L" uniqKey="Savale L">L Savale</name></author><author><name sortKey="Bergeron, A" uniqKey="Bergeron A">A Bergeron</name></author><author><name sortKey="Bourdin, A" uniqKey="Bourdin A">A Bourdin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akosman, C" uniqKey="Akosman C">C Akosman</name></author><author><name sortKey="Ordu, C" uniqKey="Ordu C">C Ordu</name></author><author><name sortKey="Eroglu, E" uniqKey="Eroglu E">E Eroglu</name></author><author><name sortKey="Oyan, B" uniqKey="Oyan B">B Oyan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sugita, Y" uniqKey="Sugita Y">Y Sugita</name></author><author><name sortKey="Ohwada, C" uniqKey="Ohwada C">C Ohwada</name></author><author><name sortKey="Nagao, Y" uniqKey="Nagao Y">Y Nagao</name></author><author><name sortKey="Kawajiri, C" uniqKey="Kawajiri C">C Kawajiri</name></author><author><name sortKey="Shimizu, R" uniqKey="Shimizu R">R Shimizu</name></author><author><name sortKey="Togasaki, E" uniqKey="Togasaki E">E Togasaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ranchoux, B" uniqKey="Ranchoux B">B Ranchoux</name></author><author><name sortKey="Gunther, S" uniqKey="Gunther S">S Günther</name></author><author><name sortKey="Quarck, R" uniqKey="Quarck R">R Quarck</name></author><author><name sortKey="Chaumais, Mc" uniqKey="Chaumais M">MC Chaumais</name></author><author><name sortKey="Dorfmuller, P" uniqKey="Dorfmuller P">P Dorfmüller</name></author><author><name sortKey="Antigny, F" uniqKey="Antigny F">F Antigny</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dumitrescu, D" uniqKey="Dumitrescu D">D Dumitrescu</name></author><author><name sortKey="Seck, C" uniqKey="Seck C">C Seck</name></author><author><name sortKey="Ten Freyhaus, H" uniqKey="Ten Freyhaus H">H ten Freyhaus</name></author><author><name sortKey="Gerhardt, F" uniqKey="Gerhardt F">F Gerhardt</name></author><author><name sortKey="Erdmann, E" uniqKey="Erdmann E">E Erdmann</name></author><author><name sortKey="Rosenkranz, S" uniqKey="Rosenkranz S">S Rosenkranz</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Montrone, D" uniqKey="Montrone D">D Montrone</name></author><author><name sortKey="Correale, M" uniqKey="Correale M">M Correale</name></author><author><name sortKey="Franzese, Mg" uniqKey="Franzese M">MG Franzese</name></author><author><name sortKey="Ieva, R" uniqKey="Ieva R">R Ieva</name></author><author><name sortKey="Di Biase, M" uniqKey="Di Biase M">M Di Biase</name></author><author><name sortKey="Capalbo, Sf" uniqKey="Capalbo S">SF Capalbo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spiekerkoetter, E" uniqKey="Spiekerkoetter E">E Spiekerkoetter</name></author><author><name sortKey="Sung, Yk" uniqKey="Sung Y">YK Sung</name></author><author><name sortKey="Sudheendra, D" uniqKey="Sudheendra D">D Sudheendra</name></author><author><name sortKey="Bill, M" uniqKey="Bill M">M Bill</name></author><author><name sortKey="Aldred, Ma" uniqKey="Aldred M">MA Aldred</name></author><author><name sortKey="Van De Veerdonk, Mc" uniqKey="Van De Veerdonk M">MC van de Veerdonk</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spiekerkoetter, E" uniqKey="Spiekerkoetter E">E Spiekerkoetter</name></author><author><name sortKey="Tian, X" uniqKey="Tian X">X Tian</name></author><author><name sortKey="Cai, J" uniqKey="Cai J">J Cai</name></author><author><name sortKey="Hopper, Rk" uniqKey="Hopper R">RK Hopper</name></author><author><name sortKey="Sudheendra, D" uniqKey="Sudheendra D">D Sudheendra</name></author><author><name sortKey="Li, Cg" uniqKey="Li C">CG Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schermuly, Rt" uniqKey="Schermuly R">RT Schermuly</name></author><author><name sortKey="Dony, E" uniqKey="Dony E">E Dony</name></author><author><name sortKey="Ghofrani, Ha" uniqKey="Ghofrani H">HA Ghofrani</name></author><author><name sortKey="Pullamsetti, S" uniqKey="Pullamsetti S">S Pullamsetti</name></author><author><name sortKey="Savai, R" uniqKey="Savai R">R Savai</name></author><author><name sortKey="Roth, M" uniqKey="Roth M">M Roth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamata, Y" uniqKey="Kamata Y">Y Kamata</name></author><author><name sortKey="Nara, H" uniqKey="Nara H">H Nara</name></author><author><name sortKey="Sato, H" uniqKey="Sato H">H Sato</name></author><author><name sortKey="Masuyama, Ji" uniqKey="Masuyama J">JI Masuyama</name></author><author><name sortKey="Minota, S" uniqKey="Minota S">S Minota</name></author><author><name sortKey="Yoshio, T" uniqKey="Yoshio T">T Yoshio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harbaum, L" uniqKey="Harbaum L">L Harbaum</name></author><author><name sortKey="Hennigs, Jk" uniqKey="Hennigs J">JK Hennigs</name></author><author><name sortKey="Baumann, Hj" uniqKey="Baumann H">HJ Baumann</name></author><author><name sortKey="Bokemeyer, C" uniqKey="Bokemeyer C">C Bokemeyer</name></author><author><name sortKey="Olschewski, H" uniqKey="Olschewski H">H Olschewski</name></author><author><name sortKey="Klose, H" uniqKey="Klose H">H Klose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ferri, C" uniqKey="Ferri C">C Ferri</name></author><author><name sortKey="Emdin, M" uniqKey="Emdin M">M Emdin</name></author><author><name sortKey="Storino, Fa" uniqKey="Storino F">FA Storino</name></author><author><name sortKey="Giuggioli, D" uniqKey="Giuggioli D">D Giuggioli</name></author><author><name sortKey="Longombardo, G" uniqKey="Longombardo G">G Longombardo</name></author><author><name sortKey="Greco, F" uniqKey="Greco F">F Greco</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meloche, J" uniqKey="Meloche J">J Meloche</name></author><author><name sortKey="Renard, S" uniqKey="Renard S">S Renard</name></author><author><name sortKey="Provencher, S" uniqKey="Provencher S">S Provencher</name></author><author><name sortKey="Bonnet, S" uniqKey="Bonnet S">S Bonnet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogawa, A" uniqKey="Ogawa A">A Ogawa</name></author><author><name sortKey="Nakamura, K" uniqKey="Nakamura K">K Nakamura</name></author><author><name sortKey="Mizoguchi, H" uniqKey="Mizoguchi H">H Mizoguchi</name></author><author><name sortKey="Fujii, N" uniqKey="Fujii N">N Fujii</name></author><author><name sortKey="Fujio, H" uniqKey="Fujio H">H Fujio</name></author><author><name sortKey="Kusano, Kf" uniqKey="Kusano K">KF Kusano</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bellotto, F" uniqKey="Bellotto F">F Bellotto</name></author><author><name sortKey="Chiavacci, P" uniqKey="Chiavacci P">P Chiavacci</name></author><author><name sortKey="Laveder, F" uniqKey="Laveder F">F Laveder</name></author><author><name sortKey="Angelini, A" uniqKey="Angelini A">A Angelini</name></author><author><name sortKey="Thiene, G" uniqKey="Thiene G">G Thiene</name></author><author><name sortKey="Marcolongo, R" uniqKey="Marcolongo R">R Marcolongo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aggarwal, M" uniqKey="Aggarwal M">M Aggarwal</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Hennigan, S" uniqKey="Hennigan S">S Hennigan</name></author><author><name sortKey="Channick, Rn" uniqKey="Channick R">RN Channick</name></author><author><name sortKey="Silverman, Gj" uniqKey="Silverman G">GJ Silverman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Padilla Ibarra, J" uniqKey="Padilla Ibarra J">J Padilla-Ibarra</name></author><author><name sortKey="Sanchez Ortiz, A" uniqKey="Sanchez Ortiz A">A Sanchez-Ortiz</name></author><author><name sortKey="Sandoval Castro, C" uniqKey="Sandoval Castro C">C Sandoval-Castro</name></author><author><name sortKey="Ramos Remus, C" uniqKey="Ramos Remus C">C Ramos-Remus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dandel, M" uniqKey="Dandel M">M Dandel</name></author><author><name sortKey="Wallukat, G" uniqKey="Wallukat G">G Wallukat</name></author><author><name sortKey="Englert, A" uniqKey="Englert A">A Englert</name></author><author><name sortKey="Hetzer, R" uniqKey="Hetzer R">R Hetzer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nagel, C" uniqKey="Nagel C">C Nagel</name></author><author><name sortKey="Ewert, R" uniqKey="Ewert R">R Ewert</name></author><author><name sortKey="Egenlauf, B" uniqKey="Egenlauf B">B Egenlauf</name></author><author><name sortKey="Lehmkuhl, Hb" uniqKey="Lehmkuhl H">HB Lehmkuhl</name></author><author><name sortKey="Rosenkranz, S" uniqKey="Rosenkranz S">S Rosenkranz</name></author><author><name sortKey="Benjamin, N" uniqKey="Benjamin N">N Benjamin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, W" uniqKey="Wang W">W Wang</name></author><author><name sortKey="Wang, Yl" uniqKey="Wang Y">YL Wang</name></author><author><name sortKey="Chen, Xy" uniqKey="Chen X">XY Chen</name></author><author><name sortKey="Li, Yt" uniqKey="Li Y">YT Li</name></author><author><name sortKey="Hao, W" uniqKey="Hao W">W Hao</name></author><author><name sortKey="Jin, Yp" uniqKey="Jin Y">YP Jin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Price, Lc" uniqKey="Price L">LC Price</name></author><author><name sortKey="Montani, D" uniqKey="Montani D">D Montani</name></author><author><name sortKey="Tcherakian, C" uniqKey="Tcherakian C">C Tcherakian</name></author><author><name sortKey="Dorfmuller, P" uniqKey="Dorfmuller P">P Dorfmüller</name></author><author><name sortKey="Souza, R" uniqKey="Souza R">R Souza</name></author><author><name sortKey="Gambaryan, N" uniqKey="Gambaryan N">N Gambaryan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Sy" uniqKey="Kim S">SY Kim</name></author><author><name sortKey="Lee, Jh" uniqKey="Lee J">JH Lee</name></author><author><name sortKey="Huh, Jw" uniqKey="Huh J">JW Huh</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author><author><name sortKey="Park, Mk" uniqKey="Park M">MK Park</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Yy" uniqKey="Wang Y">YY Wang</name></author><author><name sortKey="Luan, Y" uniqKey="Luan Y">Y Luan</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Lin, M" uniqKey="Lin M">M Lin</name></author><author><name sortKey="Zhang, Zh" uniqKey="Zhang Z">ZH Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Wang, Zs" uniqKey="Wang Z">ZS Wang</name></author><author><name sortKey="Luan, Y" uniqKey="Luan Y">Y Luan</name></author><author><name sortKey="Lin, M" uniqKey="Lin M">M Lin</name></author><author><name sortKey="Zhu, Xb" uniqKey="Zhu X">XB Zhu</name></author><author><name sortKey="Ma, Y" uniqKey="Ma Y">Y Ma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang, Jun" uniqKey="Zhang J">Jun Zhang</name></author><author><name sortKey="Lu, Wenju" uniqKey="Lu W">Wenju Lu</name></author><author><name sortKey="Chen, Yuqin" uniqKey="Chen Y">Yuqin Chen</name></author><author><name sortKey="Jiang, Qian" uniqKey="Jiang Q">Qian Jiang</name></author><author><name sortKey="Yang, Kai" uniqKey="Yang K">Kai Yang</name></author><author><name sortKey="Li, Meichan" uniqKey="Li M">Meichan Li</name></author><author><name sortKey="Wang, Ziyi" uniqKey="Wang Z">Ziyi Wang</name></author><author><name sortKey="Duan, Xin" uniqKey="Duan X">Xin Duan</name></author><author><name sortKey="Xu, Lei" uniqKey="Xu L">Lei Xu</name></author><author><name sortKey="Tang, Haiyang" uniqKey="Tang H">Haiyang Tang</name></author><author><name sortKey="Sun, Dejun" uniqKey="Sun D">Dejun Sun</name></author><author><name sortKey="Wang, Jian" uniqKey="Wang J">Jian Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, Y" uniqKey="Zhu Y">Y Zhu</name></author><author><name sortKey="Wu, Y" uniqKey="Wu Y">Y Wu</name></author><author><name sortKey="Shi, W" uniqKey="Shi W">W Shi</name></author><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Yan, X" uniqKey="Yan X">X Yan</name></author><author><name sortKey="Wang, Q" uniqKey="Wang Q">Q Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ibrahim, Yf" uniqKey="Ibrahim Y">YF Ibrahim</name></author><author><name sortKey="Wong, Cm" uniqKey="Wong C">CM Wong</name></author><author><name sortKey="Pavlickova, L" uniqKey="Pavlickova L">L Pavlickova</name></author><author><name sortKey="Liu, L" uniqKey="Liu L">L Liu</name></author><author><name sortKey="Trasar, L" uniqKey="Trasar L">L Trasar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rongioletti, F" uniqKey="Rongioletti F">F Rongioletti</name></author><author><name sortKey="Cattarini, G" uniqKey="Cattarini G">G Cattarini</name></author><author><name sortKey="Sottofattori, E" uniqKey="Sottofattori E">E Sottofattori</name></author><author><name sortKey="Rebora, A" uniqKey="Rebora A">A Rebora</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Price, Lc" uniqKey="Price L">LC Price</name></author><author><name sortKey="Wort, Sj" uniqKey="Wort S">SJ Wort</name></author><author><name sortKey="Perros, F" uniqKey="Perros F">F Perros</name></author><author><name sortKey="Dorfmuller, P" uniqKey="Dorfmuller P">P Dorfmüller</name></author><author><name sortKey="Huertas, A" uniqKey="Huertas A">A Huertas</name></author><author><name sortKey="Montani, D" uniqKey="Montani D">D Montani</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yuan, Jx" uniqKey="Yuan J">JX Yuan</name></author><author><name sortKey="Rubin, Lj" uniqKey="Rubin L">LJ Rubin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boucherat, O" uniqKey="Boucherat O">O Boucherat</name></author><author><name sortKey="Vitry, G" uniqKey="Vitry G">G Vitry</name></author><author><name sortKey="Trinh, I" uniqKey="Trinh I">I Trinh</name></author><author><name sortKey="Paulin, R" uniqKey="Paulin R">R Paulin</name></author><author><name sortKey="Provencher, S" uniqKey="Provencher S">S Provencher</name></author><author><name sortKey="Bonnet, S" uniqKey="Bonnet S">S Bonnet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tamby, Mc" uniqKey="Tamby M">MC Tamby</name></author><author><name sortKey="Chanseaud, Y" uniqKey="Chanseaud Y">Y Chanseaud</name></author><author><name sortKey="Humbert, M" uniqKey="Humbert M">M Humbert</name></author><author><name sortKey="Fermanian, J" uniqKey="Fermanian J">J Fermanian</name></author><author><name sortKey="Guilpain, P" uniqKey="Guilpain P">P Guilpain</name></author><author><name sortKey="Garcia De La Pe A Lefebvre, P" uniqKey="Garcia De La Pe A Lefebvre P">P Garcia-de-la-Peña-Lefebvre</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tamby, Mc" uniqKey="Tamby M">MC Tamby</name></author><author><name sortKey="Humbert, M" uniqKey="Humbert M">M Humbert</name></author><author><name sortKey="Guilpain, P" uniqKey="Guilpain P">P Guilpain</name></author><author><name sortKey="Servettaz, A" uniqKey="Servettaz A">A Servettaz</name></author><author><name sortKey="Dupin, N" uniqKey="Dupin N">N Dupin</name></author><author><name sortKey="Christner, Jj" uniqKey="Christner J">JJ Christner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guignabert, C" uniqKey="Guignabert C">C Guignabert</name></author><author><name sortKey="Tu, L" uniqKey="Tu L">L Tu</name></author><author><name sortKey="Le Hiress, M" uniqKey="Le Hiress M">M Le Hiress</name></author><author><name sortKey="Ricard, N" uniqKey="Ricard N">N Ricard</name></author><author><name sortKey="Sattler, C" uniqKey="Sattler C">C Sattler</name></author><author><name sortKey="Seferian, A" uniqKey="Seferian A">A Seferian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stacher, E" uniqKey="Stacher E">E Stacher</name></author><author><name sortKey="Graham, Bb" uniqKey="Graham B">BB Graham</name></author><author><name sortKey="Hunt, Jm" uniqKey="Hunt J">JM Hunt</name></author><author><name sortKey="Gandjeva, A" uniqKey="Gandjeva A">A Gandjeva</name></author><author><name sortKey="Groshong, Sd" uniqKey="Groshong S">SD Groshong</name></author><author><name sortKey="Mclaughlin, Vv" uniqKey="Mclaughlin V">VV McLaughlin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kawamura, N" uniqKey="Kawamura N">N Kawamura</name></author><author><name sortKey="Tsutsui, H" uniqKey="Tsutsui H">H Tsutsui</name></author><author><name sortKey="Fukuyama, K" uniqKey="Fukuyama K">K Fukuyama</name></author><author><name sortKey="Hayashidani, S" uniqKey="Hayashidani S">S Hayashidani</name></author><author><name sortKey="Koike, G" uniqKey="Koike G">G Koike</name></author><author><name sortKey="Egashira, K" uniqKey="Egashira K">K Egashira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mukerjee, D" uniqKey="Mukerjee D">D Mukerjee</name></author><author><name sortKey="St George, D" uniqKey="St George D">D St George</name></author><author><name sortKey="Coleiro, B" uniqKey="Coleiro B">B Coleiro</name></author><author><name sortKey="Knight, C" uniqKey="Knight C">C Knight</name></author><author><name sortKey="Denton, Cp" uniqKey="Denton C">CP Denton</name></author><author><name sortKey="Davar, J" uniqKey="Davar J">J Davar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bordley, Je" uniqKey="Bordley J">JE Bordley</name></author><author><name sortKey="Carey, Ra" uniqKey="Carey R">RA Carey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rollig, C" uniqKey="Rollig C">C Röllig</name></author><author><name sortKey="Knop, S" uniqKey="Knop S">S Knop</name></author><author><name sortKey="Bornh User, M" uniqKey="Bornh User M">M Bornhäuser</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weiner, Gj" uniqKey="Weiner G">GJ Weiner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Richardson, Pg" uniqKey="Richardson P">PG Richardson</name></author><author><name sortKey="Weller, E" uniqKey="Weller E">E Weller</name></author><author><name sortKey="Lonial, S" uniqKey="Lonial S">S Lonial</name></author><author><name sortKey="Jakubowiak, Aj" uniqKey="Jakubowiak A">AJ Jakubowiak</name></author><author><name sortKey="Jagannath, S" uniqKey="Jagannath S">S Jagannath</name></author><author><name sortKey="Raje, Ns" uniqKey="Raje N">NS Raje</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lub, S" uniqKey="Lub S">S Lub</name></author><author><name sortKey="Maes, K" uniqKey="Maes K">K Maes</name></author><author><name sortKey="Menu, E" uniqKey="Menu E">E Menu</name></author><author><name sortKey="De Bruyne, E" uniqKey="De Bruyne E">E De Bruyne</name></author><author><name sortKey="Vanderkerken, K" uniqKey="Vanderkerken K">K Vanderkerken</name></author><author><name sortKey="Van Valckenborgh, E" uniqKey="Van Valckenborgh E">E Van Valckenborgh</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="case-report"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pulm Med</journal-id><journal-title-group><journal-title>BMC Pulmonary Medicine</journal-title></journal-title-group><issn pub-type="epub">1471-2466</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31918690</article-id><article-id pub-id-type="pmc">6953266</article-id><article-id pub-id-type="publisher-id">1020</article-id><article-id pub-id-type="doi">10.1186/s12890-019-1020-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5123-8823</contrib-id><name><surname>Kreidy</surname><given-names>Mazen</given-names></name><address><email>mazenkreidy@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Al-Hilli</surname><given-names>Ali</given-names></name><address><email>Al-hilli.ali@marshfieldclinic.org</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yachoui</surname><given-names>Ralph</given-names></name><address><email>Ralph_yachoui@hotmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Resnick</surname><given-names>Jeffrey</given-names></name><address><email>Resnick.jeffrey@marshfieldclinic.org</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Pulmonary and Critical Care Medicine,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Internal Medicine,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</aff><aff id="Aff3"><label>3</label>Department of Rheumatology, Ronald Reagan UCLA Medical Center, Santa Monica, California, USA</aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9274 7048</institution-id><institution-id institution-id-type="GRID">grid.280718.4</institution-id><institution>Department of Pathology,</institution><institution>Marshfield Clinic,</institution></institution-wrap>Marshfield, WI USA</aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0444 1241</institution-id><institution-id institution-id-type="GRID">grid.414316.5</institution-id><institution>Present affiliation: Christiana Care Health System,</institution></institution-wrap>PO Box 1668, Wilmington, DE 19899 USA</aff></contrib-group><pub-date pub-type="epub"><day>9</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>9</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>20</volume><elocation-id>8</elocation-id><history><date date-type="received"><day>26</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>6</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>© The Author(s). 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Scleromyxedema is a progressive, systemic connective tissue disorder characterized by fibro-mucous skin lesions and increased serum monoclonal immunoglobulin levels. Pulmonary involvement occurs in a subset of patients, though the overall prevalence of pulmonary lesions in scleromyxedema is unknown. Since pulmonary hypertension presumably occurs in these patients due to disease progression and development of additional conditions, treatment of the underlying plasma cell dyscrasia and connective tissue disorder may improve pulmonary hypertension symptoms.</p></sec><sec><title>Case presentation</title><p id="Par2">An elderly patient with scleromyxedema developed pulmonary hypertension refractory to vasodilator and diuretic therapy and subsequently multiple myeloma that responded to a combination therapy of bortezomib, cyclophosphamide, and dexamethasone treatment.</p></sec><sec><title>Conclusions</title><p id="Par3">Treatment of the underlying disease(s) that contributed to pulmonary hypertension development with anti-neoplastic agents like bortezomib may improve cardiopulmonary symptoms secondary to reducing abnormal blood cell counts and paraprotein levels.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Scleromyxedema</kwd><kwd>Pulmonary hypertension</kwd><kwd>Multiple myeloma</kwd><kwd>Bortezomib</kwd><kwd>Cyclophosphamide</kwd><kwd>Dexamethasone</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par19">Scleromyxedema (papular mucinosis, generalized lichen myxedematous, Arndt-Gordon disease) is a rare, chronic, progressive disorder characterized by skin lesions with mucinous material deposition, fibrosis, increased population of fibroblasts, and high levels of immunoglobulins (monoclonal gammopathy of unknown significance [MGUS]) in serum without a corresponding thyroid abnormality [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. In a subset of cases described by Rongioletti et al., immune cell infiltrates may also be present in skin lesions in a “granuloma annulare-like pattern” [<xref ref-type="bibr" rid="CR7">7</xref>]. Scleromyxedema is a multi-organ disorder that can involve the nervous system, lungs, heart, kidneys, esophagus, larynx, eyes, muscles, bone marrow, and skin [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. Death can occur due to organ involvement or evolution into a blood malignancy or other cancer [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR19">19</xref>]. In a 2013 retrospective study of 30 scleromyxedema cases, two patients died from Hodgkin lymphoma or myeloid leukemia at 22 months and 11 years post-scleromyxedema diagnosis, respectively, without undergoing melphalan treatment (a chemotherapeutic agent associated with development of hematological malignancies) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Treatment generally involves modulating the immune system, decreasing the population of plasma cells, and/or improving dermatological manifestations of the disease; pharmacological and surgical treatments include intravenous immunoglobulin (IVIG), thalidomide/thalidomide derivative lealidomide, systemic glucocorticoids, melphalan, bortezomib plus dexamethasone, and autologous stem cell transplantation among others [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par20">As a dermatological condition with disease characteristics similar to scleroderma, scleromyxedema is generally classified as a connective tissue disorder with associated immune system/inflammatory responses, but due to the abnormal amounts of monoclonal immunoglobulin produced (paraproteinemia) and associated abnormal plasma cell populations, scleromyxedema is also considered a paraneoplastic and hematologic disorder [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. In these contexts, many scleromyxedema-associated syndromes can develop, including pulmonary hypertension (PH), myeloproliferative neoplasms (MPN), leukemia/lymphoma, and multiple myeloma [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>–<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>–<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR39">39</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. PH, defined by a mean pulmonary arterial pressure of ≥25 mmHg at rest, can also occur in patients with MPN and other paraneoplastic conditions, and it is demonstrated in the medical literature that PH symptoms improve in response to treatment when the underlying MPN is targeted [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]. Therefore, prescribing treatment regimens that target the overlapping pathophysiological characteristics of these associated conditions may simultaneously improve symptomology in patients with multi-system scleromyxedema [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par21">In this case report, we describe the diagnosis, treatment, and progression of PH in a patient who had scleromyxedema and developed multiple myeloma refractory to triple PH treatment that resolved with a combination treatment of bortezomib, cyclophosphamide, and dexamethasone. We propose that combination therapy with the anti-neoplastic agent bortezomib is an important adjuvant therapy to reverse vasodilator resistant PH in patients with scleromyxedema and plasma cell dyscrasias.</p><sec id="Sec2"><title>Case presentation</title><p id="Par22">A 77-year-old male nonsmoker with a history of atrial fibrillation and sick sinus syndrome post-pacemaker placement experienced edema, skin rash, and skin tightening. During the initial physical examination, yellow-brown papules and indurated and pendulous skin folds were evident on his face, neck, retroauricular area, chest, trunk, upper extremities, and thighs; he also had difficulty opening his mouth. No gross changes were observed in the digital nail beds (i.e., pitting and capillary loops) but were present in the lower extremities. Edema was present in the lower extremities. Skin biopsies revealed fibrosis and benign fibrocytic proliferation consistent with scleromyxedema (Fig. <xref rid="Fig1" ref-type="fig">1</xref>a). Colloidal iron staining for mucin deposition detected minimal interstitial mucin deposition in one biopsy, although Verhoeff van Gieson elastic stain highlighted fragmentation of superficial dermal collagen bundles (Fig. <xref rid="Fig1" ref-type="fig">1</xref>b and c). Congo red stain for amyloid deposition was negative. Aside from telangiectasia, there was no evidence of vasculopathy or thrombosis associated with these lesions. Laboratory testing of serum and urine samples detected an elevated level of immunoglobulin G (IgG) production, consistent with a diagnosis of MGUS. Electrophoresis of serum proteins revealed a total IgG level of 1500 mg/dL. Elevated levels of two IgG lambda monoclonal antibodies (~ 0.4 g/dL each) with a kappa to lambda ratio of 0.28 were detected by immunofixation of serum samples. The remaining blood values were normal for hemoglobin and calcium levels, but the patient’s kidney function was slightly above normal (creatinine level was 1.4 mg/dL and estimated glomerular filtration rate [eGFR] was 54 mL/min/1.73 m<sup>2</sup>). A 24-h urine sample was positive for lambda Bence-Jones protein at levels too low to quantitate by immunofixation. Although a skeletal survey was negative for lytic lesions, bone marrow biopsies contained 4.7% of mature looking plasma cells.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Pathology analysis of skin biopsies highlighting fibrosis and fibrocytic proliferation indicative of scleromyxedema using a Hematoxylin and Eosin stain, b colloidal iron staining for mucin deposition, and c Verhoeff van Gieson elastic stain</p></caption><graphic xlink:href="12890_2019_1020_Fig1_HTML" id="MO1"></graphic></fig></p><p id="Par23">Additional diagnostic work-up did not suggest multi-organ involvement with scleromyxedema; initial spirometry testing and diffusion lung capacity for carbon monoxide (DLCO) were within normal limits. An echocardiogram indicated the patient had diastolic dysfunction but otherwise normal right and left cardiac function and size with a normal pulmonary artery systolic pressure of 27 mmHg. He was placed on intravenous immunoglobulin G therapy at a dosage of 40 g/mL administered every 6 weeks, with a daily regimen of 60 mg prednisone and 200 mg hydroxychloroquine twice daily. There was significant improvement in the patient’s skin symptoms, and 8 weeks later, his prednisone regimen was weaned down to 5 mg per day. The patient was also started on a thalidomide regimen with an initial dose of 100 mg per day. His IgG levels decreased to 600 mg/dL after one year of maintenance therapy with this regimen.</p><p id="Par24">Over the following 4 years post-scleromyxedema diagnosis, the patient had three recurrences of dermatological symptoms of increasing severity. Episodes of acute symptoms were managed by a burst dose and tapering of steroid medication (prednisone at 60 mg daily until resolution of symptoms then a rapid taper to a maintenance dose of 5 mg daily) and increased dose of IVIG. Thalidomide treatment was discontinued 2 years later due to neuropathy, and hydroxychloroquine treatment was considered inefficient for ameliorating symptoms. During this period of time, the patient’s total IgG levels slowly increased to 1700 mg/dL with concurrent elevations in lambda monoclonal proteins ranging from 0.4–0.5 mg/dL and 0.6–0.7 mg/dL.</p><p id="Par25">At 4 years post-diagnosis, he experienced an acute episode of skin symptoms and severe dyspnea. Severely elevated levels of brain natriuretic peptide (BNP) (2650 pg/mL), indicative of cardiac strain, were detected in serum, and echocardiographic analysis revealed an enlarged right heart with depressed systolic function and an elevated pulmonary arterial systolic pressure estimated at 70 mmHg. Left ventricular function and size was normal. Abnormal pulmonary hemodynamics (in mm Hg) were measured by right heart catheterization, specifically, pulmonary artery pressures of 66/30/42, wedge pressure of 12, right ventricular pressures at 66/15, and right atrial pressure at 13. The pulmonary vascular resistance was estimated at 8.2 international units (IU), while the cardiac output was elevated at 3.65 L/min. Pulmonary function testing revealed a low DLCO at 50%. A chest computed tomography (CT) scan excluded embolism and parenchymal lung disease as contributing factors to elevated right heart dimensions and pulmonary hemodynamics. Additional laboratory testing of serum proteins detected elevated levels of IgG proteins (3670 mg/dL) and the two lambda monoclonal proteins (1.6 g/dL and 1.3 g/dL). A follow-up bone marrow biopsy revealed an ~ 10% normal appearing population of plasma cells that were considered reactive to the patient’s underlying scleromyxedema.</p><p id="Par26">Based on the cardiovascular, pulmonary, and hematological analyses, the patient was diagnosed with a scleromyxedema flare with associated pulmonary arterial hypertension (PAH). He was initially placed on a dual treatment regimen for PAH consisting of 40 mg tadalafil once daily and ambrisentan 5 mg daily that was later increased to 10 mg daily. In addition to increasing the ambrisentan dosage, a daily dose of 40 mg lasix was added to the PAH treatment. Scleromyxedema treatment was optimized with the addition of intravenous chimeric antibodies against CD20 (rituximab) at a dosage and frequency similar to a protocol for rheumatoid arthritis, specifically 1 g of rituximab on days 1 and 15 of the treatment cycle over a period of 24 weeks for a total regimen of three cycles. A burst-taper dose of prednisone was also administered (60 mg, tapered over the next 8 weeks). Over the following year, inhaled trepostinil (vasodilator) was added to the PAH regimen for persistently elevated pulmonary arterial systolic pressure at 42 mmHg and right heart strain on cardiac echography.</p><p id="Par27">On this treatment regimen, the patient’s acute symptoms improved, and he maintained a New York Heart Association (NYHA) functional status of class II. Although the patient’s serum BNP levels decreased to 300 pg/mL, echocardiographic analysis continued to show depressed right heart function and elevated pulmonary arterial pressure at 43 mmHg. A polysomnographic analysis indicated the patient had developed obstructive sleep apnea (Apnea–Hypopnea Index [AHI] of 24 events/hour), and he was subsequently treated with continuous positive airway pressure (CPAP) at 10 cmH2O. Intravenous prostacyclin therapy was considered for PAH, but the patient declined. Follow-up immunoglobulin analysis revealed decreased IgG levels (2060 mg/dL).</p><p id="Par28">Despite maintenance therapy with IVIG and rituximab, the patient developed another severe recurrence of his skin symptoms and worsening dyspnea at 6 years post-scleromyxedema diagnosis (2 years post-PAH diagnosis). Follow-up echocardiography revealed a new left ventricular cardiomyopathy with an ejection fraction of 40%, persistent elevated pulmonary arterial pressure at 44 mmHg, and persistent right ventricular dilation. Serum BNP levels were elevated at 631 pg/mL, and IgG levels had increased to 3420 mg/dL with concurrent elevations of the two monoclonal lambda proteins at 1.48 and 0.37 g/dL. A follow-up bone marrow biopsy revealed an abnormal plasma cell population of 60% consistent with a hematological abnormality. The patient was diagnosed with multiple myeloma associated with an acute episode of scleromyxedema flare up with multi-organ involvement. A treatment regimen of bortezomib (2 mg; dose adjusted per cycle depending on patient-related factors as denoted in Table <xref rid="Tab1" ref-type="table">1</xref>) and dexamethasone (20 mg) (4 weeks per cycle of therapy) was initiated to decrease the plasma cell population, and IVIG treatment was continued to alleviate dermatological symptoms. Over the following 2 years, the patient received a total of seven cycles of bortezomib and dexamethasone (Table <xref rid="Tab1" ref-type="table">1</xref>). There was a dramatic improvement in his PAH, cardiovascular, and dermatological symptoms. Serum analysis revealed decreased BNP and IgG levels at 100 pg/mL and 1300 mg, respectively. A repeat echocardiogram revealed significant improvement in right ventricular size and function as well as left ventricular function, but pulmonary arterial systolic pressure was still elevated at 51 mmHg. However, bortezomib had to be discontinued after the seventh cycle due to worsening neuropathy. A treatment regimen with a lenalidomide derivative (Revlimid) was attempted but also discontinued after 2 months of treatment due to adverse side effects. The patient elected to halt the inhaled trepostinil regimen.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Chemotherapeutic regimens administered with bortezomib for treatment of multiple myeloma and pre-existing scleromyxedema with pulmonary symptoms</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Cycle #</th><th>Agent 1</th><th>Dose</th><th>Agent 2</th><th>Dose</th><th>Agent 3</th><th>Dose</th><th>Agent 4</th><th>Dose</th></tr></thead><tbody><tr><td>1</td><td>Bortezomib D1, D8, D15</td><td>2.5 IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>IVIG Weekly</td><td>40 g IV</td><td>–</td><td>–</td></tr><tr><td>2</td><td>Bortezomib D1, D8, D15</td><td>2.6 S/Q</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>IVIG Weekly</td><td>40 g IV</td><td>–</td><td>–</td></tr><tr><td>3</td><td>Bortezomib D1, D8, D15</td><td>2.6 S/Q</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>IVIG Weekly</td><td>40 g IV</td><td>–</td><td>–</td></tr><tr><td>4</td><td>Bortezomib D1, D8, D15</td><td>2.6 S/Q</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>IVIG Weekly</td><td>40 g IV</td><td>–</td><td>–</td></tr><tr><td>5</td><td>Bortezomib D1, D8, D15</td><td>2.6 S/Q</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>IVIG Weekly</td><td>40 g IV</td><td>–</td><td>–</td></tr><tr><td>6</td><td>Bortezomib D1, D8, D15</td><td>2.6 S/Q</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>IVIG Weekly</td><td>40 g IV</td><td>–</td><td>–</td></tr><tr><td>7</td><td>Bortezomib D1 only, developed neuropathy</td><td>2.6 S/Q</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>IVIG Weekly</td><td>40 g IV</td><td></td><td></td></tr><tr><td>1</td><td>Bortezomib D1, D8, D15</td><td>1.5 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>300 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>2</td><td>Bortezomib D1, D8, D15</td><td>1.5 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>300 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>3</td><td>Bortezomib D1, D8, D15</td><td>1.6 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>600 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>4</td><td>Bortezomib D1, D8, D15</td><td>1.6 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>600 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td colspan="2">Chemotherapy break–</td><td>–</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>–</td><td>–</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>5</td><td>Bortezomib D1, D8, D15</td><td>1.2 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>600 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>6</td><td>Bortezomib D1, D8, D15</td><td>1.5 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>480 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>7</td><td>Bortezomib D1, D8, D15</td><td>2 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>600 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>8</td><td>Bortezomib D1, D8, D15</td><td>1.6 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>600 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td>9</td><td>Bortezomib D1, D8, D15</td><td>2 mg IV</td><td>Dexamethasone Weekly</td><td>20 mg PO</td><td>Cyclophosphamide D1, D8, D15</td><td>500 mg IV</td><td>IVIG Weekly</td><td>40 g IV</td></tr><tr><td></td><td>Iron infusion</td><td>510 mg IV</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>Passed away</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td><td>N/A</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: <italic>D#</italic> Day of treatment cycle, <italic>IV</italic> Intravenous Injection, <italic>IVIG</italic> Intravenous Immunoglobulin, <italic>N/A</italic> Not applicable, <italic>PO</italic> Per Os (oral), <italic>S/Q</italic> Subcutaneos Injection, − unknown</p></table-wrap-foot></table-wrap></p><p id="Par29">The patient was observed for ~ 14 months before he experienced a recurrence of symptoms and cardiopulmonary decline. His IgG levels had again increased to 2000 mg/dL. The patient was placed on a weekly regimen of 3 mg bortezomib, 20 mg dexamethasone, and 600 mg of cyclophosphamide (Cytoxan) (4 weeks per cycle, last dose omitted because of pancytopenia), and IVIG maintenance therapy was continued at a dosage of 40 g/mL (see Table <xref rid="Tab1" ref-type="table">1</xref> for dose adjustments per cycle). After four cycles, the patient’s symptoms improved, and his IgG levels decreased to the lowest concentration of 1100 mg/dL. Only one monoclonal lambda protein was detected at 0.52 mg/dL. An echocardiogram revealed normalization of left and right ventricular size and function as well as normalization of pulmonary arterial systolic pressure at 23 mmHg.</p><p id="Par30">After a treatment break of 6 months, the patient’s symptoms recurred, and his IgG levels increased above 2000 mg/dL. The patient underwent five additional cycles of bortezomib, dexamethasone, and cyclophosphamide. His IgG levels stabilized between 2000 and 2500 mg/dL, and a repeat bone marrow biopsy revealed a decrease in the abnormal plasma cell population to 22%. A follow-up echocardiogram revealed normal right and left ventricular size and function and a mildly elevated pulmonary arterial systolic pressure at 38 mmHg. Future plans for the patient’s care involved slowly weaning him from his vasodilator medications; however, he suffered a sudden and fatal out-of-hospital cardiac arrest of unclear etiology at 9 years post-scleromyxedema diagnosis. No autopsy was performed.</p></sec></sec><sec id="Sec3"><title>Discussion</title><p id="Par31">Pulmonary hypertension has occurred in association with various hematologic malignancies, particularly those with underlying plasma cell dyscrasias [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]. The first case of reversible PH in response to antineoplastic treatment for a scleromyxedema-like condition and hematological malignancy was described by Yaqub et al. in 2004, and in 2015, Feyereisn described the diagnosis, treatment, and outcome of four cases of reversible PH in the setting of plasma cell dyscrasias one of which had scleromyxedema [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The overall frequency and spectrum of PH in this setting remains largely undefined.</p><p id="Par32">In our patient with scleromyxedema, multiple anti-neoplastic and immunomodulatory treatment regimens were used to alleviate dermatological and cardiopulmonary symptoms. Immunomodulatory treatments like IVIG, glucocorticoids, and hydroxychloroquine were administered over the entire course of the disease but were unable to produce a complete remission of skin and cardiopulmonary symptoms. Administration of anti-neoplastic agents like thalidomide and bortezomib led to decreased paraprotein levels on multiple occasions and corresponded to improved pulmonary dynamics in a manner similar to previously published cases [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Close monitoring and treatment alteration was necessary to prevent unanticipated clinical events. Thalidomide or thalidomide derivatives were used at two points over the course of this patient’s history but were halted due to development of neuropathy and other adverse side effects. Although anti-neoplastic/chemotherapeutic agents can be associated with the development of PH, pulmonary injury, and hematological malignancies, we do not believe this occurred based on the temporal progression of scleromyxedema from a localized cutaneous condition to a generalized disease with multiple phenotypes over a period of 9 years [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR80">80</xref>]. Furthermore, PH developed 2 years after thalidomide treatment was stopped, and cardiopulmonary symptoms for the most part resolved in response to multiple myeloma treatment. Despite a partial therapeutic response with respect to abnormal plasma cell populations and IgG production, this patient experienced excellent recovery of cardiopulmonary function when on anti-neoplastic treatment regimens. Thus, a complete remission of scleromyxedema and associated plasma cell dyscrasia and paraprotein levels does not appear to be necessary to obtain a significant improvement in PH symptoms.</p><p id="Par33">Although the physiopathology of PH development in response to plasma cell dyscrasias has not been fully elucidated, the reversibility of hemodynamics in response to treatment with chemotherapeutic and immunomodulatory agents offers hope for PAH patients [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR81">81</xref>–<xref ref-type="bibr" rid="CR103">103</xref>]. Improvements in hematopoietic cell populations, paraprotein levels, and hemodynamic functions in our patient and other cases of reversible PH suggest that abnormal plasma cell populations play a central role in the development of PH [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR84">84</xref>–<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR91">91</xref>]. Furthermore, patients with scleromyxedema and related conditions who received treatments traditionally used for multiple myeloma have exhibited decreases in IgG and paraprotein levels that co-occurred with clinical improvements, as in our patient [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. This may also indicate a direct link between decreased paraprotein levels and hemodynamic improvements by way of improved hyperviscosity and associated microvascular dysfunction [<xref ref-type="bibr" rid="CR8">8</xref>]. However, detectable paraprotein levels are not always present nor correspond to the severity, progression, and response of scleromyxedema to standard treatments for this condition; therefore, the relative contribution of scleromyxedema progression and paraprotein levels to PH development is unclear [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. Other pathobiological mechanisms invoked in the development of scleromyxedema and/or associated with plasma cell dyscrasias may also contribute to the development of PAH. These include increased secretion and expression of cytokines, dysregulation of immune system activities, and/or abnormal pulmonary fibroblasts, mucin deposition in the pulmonary vasculature, and direct invasion of the pulmonary vasculature by abnormal plasma cells [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR104">104</xref>–<xref ref-type="bibr" rid="CR111">111</xref>]. Alternatively, a direct effect of chemotherapeutic agents on the pulmonary vasculature and associated abnormal humoral milieus may also have played a role in this reversibility. Due to the multifaceted nature of PH development and reversibility in response to treatment, it is also possible that a multi-hit model, as in idiopathic pulmonary arterial hypertension (IPAH), is plausible [<xref ref-type="bibr" rid="CR106">106</xref>]. Regardless of the underlying etiology, patients with concurrent PH and MPN or vice versa have demonstrated hemodynamic improvements in response to chemotherapeutic agents; thus, patients with vasodilator-resistant PH may derive benefit from cancer treatments [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR63">63</xref>].</p><p id="Par34">Evidence for a cancer-like pathology and direct effects of immunosuppressive and anti-proliferative agents on PH development and progression is present in case reports for patients with PAH [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>–<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR60">60</xref>–<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR85">85</xref>–<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR90">90</xref>–<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR105">105</xref>–<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR113">113</xref>]. According to Price et al., “Pathologic specimens from patients with PAH demonstrate an accumulation of perivascular inflammatory cells,” and laboratory analysis of serum from patients with PAH revealed increased levels of cytokines, chemokines as well as autoantibodies to endothelial cells and fibroblasts [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR108">108</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. In parallel to those abnormalities, the pulmonary vascular cells of patients with PAH exhibit many features of cancerous cells from dysregulated metabolism to increased cell proliferation and resistance to apoptosis [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR109">109</xref>]. These observations combined with the occurrence of PAH in various connective tissue diseases support the role of inflammation, autoimmunity, and a neoplastic-like dysregulation at the center of the pathogenesis of PAH [<xref ref-type="bibr" rid="CR105">105</xref>–<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR110">110</xref>–<xref ref-type="bibr" rid="CR113">113</xref>]. This model could provide a mechanistic explanation for the hemodynamic improvements noted in our patient and in many patients with PAH in response to immunosuppressive and anti-proliferative agents [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR63">63</xref>]. The following paragraphs provide a description of currently used agents for multiple myeloma and/or scleromyxedema that have proven effective for patients with PAH.</p><p id="Par35">Glucocorticoids have an inhibitory effect on multiple types of immune cells and produce broad anti-inflammatory and immunosuppressive effects [<xref ref-type="bibr" rid="CR114">114</xref>]. Glucocorticoids have been used as a treatment for scleromyxedema with positive effects reported in single case reports, and its efficacy against collagen disease-associated PAH is well known [<xref ref-type="bibr" rid="CR31">31</xref>–<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR88">88</xref>–<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR112">112</xref>–<xref ref-type="bibr" rid="CR114">114</xref>]. Glucocorticoids are also used as a first line therapy for multiple myeloma in combination with other chemotherapy regimens in patients ineligible for autologous stem cell transplantation [<xref ref-type="bibr" rid="CR115">115</xref>]. Improvements post-prednisolone treatment have been noted in adult and pediatric patients with iPAH as well as in monocrotaline-induced pulmonary arterial hypertension in rodents [<xref ref-type="bibr" rid="CR88">88</xref>–<xref ref-type="bibr" rid="CR90">90</xref>, <xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>].</p><p id="Par36">Rituximab is an FDA-approved chimeric anti-CD20 monoclonal antibody for various malignancies and autoimmune disorders [<xref ref-type="bibr" rid="CR116">116</xref>]. It exerts its immunosuppressive and anti-proliferative effects through antibody- and complement-mediated dependent cellular toxicity and apoptosis and has been used anecdotally for mixed connective tissue disorders [<xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR116">116</xref>]. Previously published case reports demonstrated improvements in collagen vascular disease-associated PAH in response to rituximab treatment, and a large randomized placebo controlled clinical trial of rituximab for the treatment of scleroderma-associated PAH is currently underway (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> identifier NCT01086540) [<xref ref-type="bibr" rid="CR92">92</xref>, <xref ref-type="bibr" rid="CR93">93</xref>]. In a presumed case of iPAH, rituximab co-treatment with chemotherapy for lymphoma lead to symptom resolution, and PAH in the setting of Castleman lymphoma was also noted to respond to rituximab [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR85">85</xref>]. However, in two instances, rituximab use was associated with the development of PH [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>].</p><p id="Par37">Plasma exchange or plasmapheresis is an automated technique that permits the selective therapeutic exchange of patient plasma with another fluid. Plasma exchange has been suggested as a treatment for scleromyxedema and was noted to improve PAH in association with various connective tissue diseases [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Immunoadsorption (IA), another extracorporeal automated technique to selectively remove immunoglobulins from the plasma of PAH patients via high affinity absorbers, is a promising treatment for iPAH; in 5 patients with severe iPAH awaiting transplant, IA improved symptoms associated with iPAH [<xref ref-type="bibr" rid="CR94">94</xref>]. IA as an add-on to targeted medical therapy also led to improvements in mean PVR and CI in 10 patients with iPAH though these hemodynamic improvements did not correlate to substantial improvements in the 6 mn walk test [<xref ref-type="bibr" rid="CR95">95</xref>].</p><p id="Par38">Bortezomib is a proteasome inhibitor that is FDA-approved for the treatment of multiple myeloma [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. In the medical literature, patients with multiple myeloma and PH can experience reversal of PH symptoms with bortezomib treatment, although adverse pulmonary effects have also been reported in association with this drug [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. Steroid co-treatments can prevent bortezomib-induced lung injury, though additional studies are needed to assess both the adverse pulmonary side effects as well as the protective effect of an adjuvant steroid regimen for bortezomib treatment [<xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. In animal models of pulmonary disease, bortezomib treatment reverses adverse cardiopulmonary effects and can improve survival post-monocrotaline-induced PH/PAH [<xref ref-type="bibr" rid="CR98">98</xref>–<xref ref-type="bibr" rid="CR103">103</xref>]. In a mouse model of hypoxia-induced PH, bortezomib treatment prevented an increase in right ventricular systolic pressure, ratio of right ventricular weight to left ventricular weight and septum (right ventricular hypertrophy index), percent medial wall thickness, and muscularization of pulmonary vessels and inhibited vascular smooth muscle proliferation [<xref ref-type="bibr" rid="CR98">98</xref>]. A similar treatment effect was observed in rats with monocrotaline- or left-to-right shunt-induced PAH, and bortezomib treatment also enhanced survival in monocrotaline-injected rats compared to monocrotaline-injected rats without bortezomib treatment [<xref ref-type="bibr" rid="CR98">98</xref>–<xref ref-type="bibr" rid="CR102">102</xref>]. In a chronic hypoxia-induced PAH rat model, Ibrahim and colleagues noted that anti-tumor agents, specifically bortezomib, MG-132, and daunorubicin, decreased pulmonary vessel thickness and, in the case of daunorubicin and MG-132, improved pulmonary response to vasodilator treatment [<xref ref-type="bibr" rid="CR103">103</xref>]. Together, these results suggest that proteasome inhibitors alone or in combination with vasodilators could potentially prevent and/or reverse PAH-induced pulmonary vessel remodeling and hemodynamic response in PAH afflicted patients [<xref ref-type="bibr" rid="CR98">98</xref>–<xref ref-type="bibr" rid="CR103">103</xref>].</p><p id="Par39">Regardless of the agent selected, it is clear from our and previous cases that PH/PAH can be improved by the addition of anti-neoplastic agents to the overall treatment regimen of patients with conditions that produce plasma cell dyscrasias, abnormal protein levels, and increased extracellular matrix deposition [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR57">57</xref>–<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR81">81</xref>–<xref ref-type="bibr" rid="CR103">103</xref>]. However, these therapies can produce adverse side effects that may potentially limit the number and type of treatments available for PH, multiple myeloma, and other conditions associated with multi-system scleromyxedema [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR64">64</xref>–<xref ref-type="bibr" rid="CR80">80</xref>]. Careful monitoring is necessary to mitigate adverse treatment effects in this patient population.</p></sec><sec id="Sec4"><title>Conclusion</title><p id="Par40">Although bortezomib and cyclophosphamide are generally used as second- and third-line treatments for scleromyxedema and related cutaneous mucinoses, these agents may be an effective primary therapy for these conditions in combination with glucocorticoids and/or proteasome inhibitors [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR87">87</xref>] especially in the presence of plasma cell dyscrasia-associated PAH. Treatment of our patient’s underlying plasma cell abnormality with a combination treatment of cyclophosphamide, bortezomib, and dexamethasone not only reduced the population of abnormal plasma cells in the bone marrow but also improved the dermatological, cardiopulmonary, and paraprotein effects of scleromyxedema and multiple myeloma-induced PH as well similar to a few other previously reported cases [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Therefore, a combination regimen of cyclophosphamide, dexamethasone, and bortezomib may be an effective multi-target treatment for patients with PH refractory to vasodilator treatment, in the setting of plasma cell dyscrasias and elevated paraprotein levels. Additional work is necessary to understand the physiology of chemotherapeutic agents for PAH-associated plasma cell dyscrasias and develop treatment regimens to maximize clinical response with minimal side effects.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AHI</term><def><p id="Par4">Apnea–Hypopnea Index</p></def></def-item><def-item><term>BNP</term><def><p id="Par5">Brain natriuretic peptide</p></def></def-item><def-item><term>CPAP</term><def><p id="Par6">Continuous positive airway pressure</p></def></def-item><def-item><term>CT</term><def><p id="Par7">Computed tomography</p></def></def-item><def-item><term>DLCO</term><def><p id="Par8">Diffusion lung capacity for carbon monoxide</p></def></def-item><def-item><term>eGFR</term><def><p id="Par9">Estimated glomerular filtration rate</p></def></def-item><def-item><term>IgG</term><def><p id="Par10">Immunoglobulin G</p></def></def-item><def-item><term>IU</term><def><p id="Par11">International units</p></def></def-item><def-item><term>IVIG</term><def><p id="Par12">Intravenous immunoglobulin</p></def></def-item><def-item><term>MGUS</term><def><p id="Par13">Monoclonal gammopathy of unknown significance</p></def></def-item><def-item><term>MPN</term><def><p id="Par14">Myeloproliferative neoplasms</p></def></def-item><def-item><term>NYHA</term><def><p id="Par15">New York Heart Association</p></def></def-item><def-item><term>PAH</term><def><p id="Par16">Pulmonary Arterial Hypertension</p></def></def-item><def-item><term>PH</term><def><p id="Par17">Pulmonary Hypertension</p></def></def-item><def-item><term>POEMS</term><def><p id="Par18">Polyneuropathy, organomegaly, endocrinopathy/edema, M-protein, skin changes</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher’s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank Emily Andreae, PhD, and Marie Fleisner for manuscript preparation and submission.</p></ack><notes notes-type="author-contribution"><title>Authors’ contributions</title><p>All authors contributed to the preparation of this manuscript and have read and approved the final manuscript. <italic>Individual contributions:</italic> MK managed the patient’s pulmonary hypertension and led the preparation, writing, and revising of the manuscript. AAH tracked the patient’s chemotherapy schedule and generated the treatment tables for this manuscript. RY is the rheumatologist representing the department who managed the patient’s scleromyxedema and provided input from a rheumatological standpoint for the manuscript. JR prepared, analyzed, and interpreted pathology specimens.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study. A complete listing of data from the patient’s electronic medical record is unavailable for viewing, sharing, or dissemination per HIPAA guidelines.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par41">As this manuscript meets the definition of a case report, Institutional Review Board (IRB) review was not required for publication; the Marshfield Clinic Health System’s IRB does not require written patient consent unless identifiable information (i.e., facial photographs) is published. Care was provided in accordance with standard-of-care procedures and best-practice recommendations at the health care system. Convenience.</p></notes><notes><title>Consent for publication</title><p id="Par42">We confirm that we have obtained verbal consent to publish from the patient/participant to report the individual patient’s data and medical images. Verbal consent was obtained from the patient. We have also now obtained written informed consent from the wife of the patient, after he passed away.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par43">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>JT</given-names></name><name><surname>Osserman</surname><given-names>E</given-names></name><name><surname>Lombardo</surname><given-names>PC</given-names></name><name><surname>Takatsuki</surname><given-names>K</given-names></name></person-group><article-title>An abnormal serum globulin in lichen myxedematosus</article-title><source>Arch Dermatol</source><year>1964</year><volume>89</volume><fpage>446</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1001/archderm.1964.01590270132030</pub-id><pub-id pub-id-type="pmid">14096371</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>SE</given-names></name><name><surname>Perry</surname><given-names>HO</given-names></name><name><surname>Oleson</surname><given-names>GB</given-names></name><name><surname>Bowles</surname><given-names>CA</given-names></name></person-group><article-title>Scleromyxedema: a scleroderma-like disorder with systemic manifestations</article-title><source>Medicine (Baltimore)</source><year>1988</year><volume>67</volume><issue>1</issue><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1097/00005792-198801000-00004</pub-id><pub-id pub-id-type="pmid">3336281</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinneen</surname><given-names>AM</given-names></name><name><surname>Dicken</surname><given-names>CH</given-names></name></person-group><article-title>Scleromyxedema</article-title><source>J Am Acad Dermatol</source><year>1995</year><volume>33</volume><issue>1</issue><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/0190-9622(95)90007-1</pub-id><pub-id pub-id-type="pmid">7601944</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006;24(6):493–7.</mixed-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>M</given-names></name><name><surname>Wigley</surname><given-names>FM</given-names></name><name><surname>Hummers</surname><given-names>LK</given-names></name></person-group><article-title>Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG)</article-title><source>Medicine (Baltimore)</source><year>2008</year><volume>87</volume><issue>1</issue><fpage>10</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1097/MD.0b013e3181630835</pub-id><pub-id pub-id-type="pmid">18204366</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rongioletti</surname><given-names>F</given-names></name><name><surname>Merlo</surname><given-names>G</given-names></name><name><surname>Cinotti</surname><given-names>E</given-names></name><name><surname>Fausti</surname><given-names>V</given-names></name><name><surname>Cozzani</surname><given-names>E</given-names></name><name><surname>Cribier</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients</article-title><source>J Am Acad Dermatol</source><year>2013</year><volume>69</volume><issue>1</issue><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2013.01.007</pub-id><pub-id pub-id-type="pmid">23453242</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rongioletti</surname><given-names>F</given-names></name><name><surname>Merlo</surname><given-names>G</given-names></name><name><surname>Carli</surname><given-names>C</given-names></name><name><surname>Cribier</surname><given-names>B</given-names></name><name><surname>Metze</surname><given-names>D</given-names></name><name><surname>Calonje</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases</article-title><source>J Am Acad Dermatol</source><year>2016</year><volume>74</volume><issue>6</issue><fpage>1194</fpage><lpage>1200</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2015.12.021</pub-id><pub-id pub-id-type="pmid">26897387</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Rongioletti F. Scleromyxedema. Callen J, ed. UpToDate. Waltham: Wolters Kluwer. UpToDate Inc <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com">http://www.uptodate.com</ext-link>. Accessed on 22 Aug 2017.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreli</surname><given-names>C</given-names></name><name><surname>Gasparini</surname><given-names>G</given-names></name><name><surname>Parodi</surname><given-names>A</given-names></name><name><surname>Cozzani</surname><given-names>E</given-names></name><name><surname>Rongioletti</surname><given-names>F</given-names></name><name><surname>Atzori</surname><given-names>L</given-names></name></person-group><article-title>Cutaneous manifestations of scleroderma and scleroderma-like disorders: a comprehensive review</article-title><source>Clin Rev Allergy Immunol</source><year>2017</year><volume>53</volume><issue>3</issue><fpage>306</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1007/s12016-017-8625-4</pub-id><pub-id pub-id-type="pmid">28712039</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knobler</surname><given-names>R</given-names></name><name><surname>Moinzadeh</surname><given-names>P</given-names></name><name><surname>Hunzelmann</surname><given-names>N</given-names></name><name><surname>Kreuter</surname><given-names>A</given-names></name><name><surname>Cozzio</surname><given-names>A</given-names></name><name><surname>Mouthon</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 2: Scleromyxedema, scleredema and nephrogenic s ystemic fibrosis</article-title><source>J Eur Acad Dermatol Venereol</source><year>2017</year><volume>31</volume><issue>9</issue><fpage>1581</fpage><lpage>1594</lpage><pub-id pub-id-type="doi">10.1111/jdv.14466</pub-id><pub-id pub-id-type="pmid">28786499</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rongioletti</surname><given-names>F</given-names></name></person-group><article-title>Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease</article-title><source>Semin Cutan Med Surg</source><year>2006</year><volume>25</volume><fpage>100</fpage><pub-id pub-id-type="doi">10.1016/j.sder.2006.04.001</pub-id><pub-id pub-id-type="pmid">16908401</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>AS</given-names></name><name><surname>Schulz</surname><given-names>EJ</given-names></name><name><surname>Falkson</surname><given-names>G</given-names></name><name><surname>Simson</surname><given-names>IW</given-names></name><name><surname>Coccia-Portugal</surname><given-names>MA</given-names></name></person-group><article-title>Normalization of skin appearance in a patient with scleromyxoedema after intensive chemotherapy for Hodgkin's disease</article-title><source>Dermatol</source><year>1989</year><volume>178</volume><issue>4</issue><fpage>221</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1159/000248432</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giménez Garcia</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>SG</given-names></name><name><surname>Suarez Vilela</surname><given-names>D</given-names></name><name><surname>Moro Sanchez</surname><given-names>MJ</given-names></name></person-group><article-title>Scleromyxedema associated with non-Hodgkin lymphoma</article-title><source>Int J Dermatol</source><year>1989</year><volume>28</volume><issue>10</issue><fpage>670</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4362.1989.tb02439.x</pub-id><pub-id pub-id-type="pmid">2592130</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godby</surname><given-names>A</given-names></name><name><surname>Bergstresser</surname><given-names>PR</given-names></name><name><surname>Chaker</surname><given-names>B</given-names></name><name><surname>Pandya</surname><given-names>AG</given-names></name></person-group><article-title>Fatal scleromyxedema: report of a case and review of the literature</article-title><source>J Am Acad Dermatol</source><year>1998</year><volume>38</volume><issue>2 Pt 2</issue><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(98)70567-5</pub-id><pub-id pub-id-type="pmid">9486700</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loggini</surname><given-names>B</given-names></name><name><surname>Pingitore</surname><given-names>R</given-names></name><name><surname>Avvenente</surname><given-names>A</given-names></name><name><surname>Giuliano</surname><given-names>G</given-names></name><name><surname>Barachini</surname><given-names>P</given-names></name></person-group><article-title>Lichen myxedematosus with systemic involvement: clinical and autopsy findings</article-title><source>J Am Acad Dermatol</source><year>2001</year><volume>45</volume><issue>4</issue><fpage>606</fpage><lpage>608</lpage><pub-id pub-id-type="doi">10.1067/mjd.2001.111903</pub-id><pub-id pub-id-type="pmid">11568755</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Simone</surname><given-names>C</given-names></name><name><surname>Castriota</surname><given-names>M</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>Marini Bettolo</surname><given-names>P</given-names></name><name><surname>Pieroni</surname><given-names>M</given-names></name><name><surname>Rongioletti</surname><given-names>F</given-names></name></person-group><article-title>Cardiomyopathy in scleromyxedema: Report of a fatal case</article-title><source>Eur J Dermatol</source><year>2010</year><volume>20</volume><issue>6</issue><fpage>852</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">20977988</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fett</surname><given-names>NM</given-names></name><name><surname>Toporcer</surname><given-names>MB</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Shinohara</surname><given-names>MM</given-names></name><name><surname>Vogl</surname><given-names>DT</given-names></name></person-group><article-title>Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib</article-title><source>Am J Hematol</source><year>2011</year><volume>86</volume><issue>10</issue><fpage>893</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1002/ajh.22131</pub-id><pub-id pub-id-type="pmid">22026006</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>AC</given-names></name><name><surname>Cunha</surname><given-names>PR</given-names></name><name><surname>Pinto</surname><given-names>CA</given-names></name><name><surname>Alves</surname><given-names>CA</given-names></name><name><surname>Paiva</surname><given-names>IB</given-names></name><name><surname>Araujo</surname><given-names>AP</given-names></name></person-group><article-title>Scleromyxedema: clinical diagnosis and autopsy findings</article-title><source>An Bras Dermatol</source><year>2016</year><volume>91</volume><issue>5 suppl 1</issue><fpage>48</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1590/abd1806-4841.20164527</pub-id><pub-id pub-id-type="pmid">28300892</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muldrow</surname><given-names>ML</given-names></name><name><surname>Bailin</surname><given-names>PL</given-names></name></person-group><article-title>Scleromyxedema associated with IgG lambda multiple myeloma</article-title><source>Cleve Clin Q</source><year>1983</year><volume>50</volume><issue>2</issue><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.3949/ccjm.50.2.189</pub-id><pub-id pub-id-type="pmid">6416712</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>CK</given-names></name><name><surname>Loong</surname><given-names>F</given-names></name><name><surname>Kwong</surname><given-names>YL</given-names></name></person-group><article-title>Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone</article-title><source>Br J Haematol</source><year>2012</year><volume>157</volume><issue>4</issue><fpage>411</fpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2012.09088.x</pub-id><pub-id pub-id-type="pmid">22429092</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>R</given-names></name><name><surname>de Waal</surname><given-names>EG</given-names></name><name><surname>Kuiper</surname><given-names>H</given-names></name><name><surname>Hazenberg</surname><given-names>BP</given-names></name><name><surname>Vellenga</surname><given-names>E</given-names></name></person-group><article-title>Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema</article-title><source>Rheumatol (Oxf)</source><year>2011</year><volume>50</volume><issue>10</issue><fpage>1925</fpage><lpage>1926</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/ker209</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cañueto</surname><given-names>J</given-names></name><name><surname>Labrador</surname><given-names>J</given-names></name><name><surname>Román</surname><given-names>C</given-names></name><name><surname>Santos-Briz</surname><given-names>A</given-names></name><name><surname>Contreras</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: A rare disease with new clinical insights</article-title><source>Eur J Haematol</source><year>2012</year><volume>88</volume><issue>5</issue><fpage>450</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2012.01772.x</pub-id><pub-id pub-id-type="pmid">22404151</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migkou</surname><given-names>M</given-names></name><name><surname>Gkotzamanidou</surname><given-names>M</given-names></name><name><surname>Terpos</surname><given-names>E</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><name><surname>Kastritis</surname><given-names>E</given-names></name></person-group><article-title>Response to bortezomib of a patient with scleromyxedema refractory to other therapies</article-title><source>Leuk Res</source><year>2011</year><volume>35</volume><issue>11</issue><fpage>e209</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2011.07.021</pub-id><pub-id pub-id-type="pmid">21831425</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaqub</surname><given-names>S</given-names></name><name><surname>Moder</surname><given-names>KG</given-names></name><name><surname>Lacy</surname><given-names>MQ</given-names></name></person-group><article-title>Severe, reversible pulmonary hypertension in a patient with monoclonal gammopathy and features of dermatomyositis</article-title><source>Mayo Clin Proc</source><year>2004</year><volume>79</volume><issue>5</issue><fpage>687</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.4065/79.5.687</pub-id><pub-id pub-id-type="pmid">15132415</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feyereisn</surname><given-names>WL</given-names></name><name><surname>Fenstad</surname><given-names>ER</given-names></name><name><surname>McCully</surname><given-names>RB</given-names></name><name><surname>Lacy</surname><given-names>MQ</given-names></name></person-group><article-title>Severe reversible pulmonary hypertension in smoldering multiple myeloma: two cases and review of the literature</article-title><source>Pulm Circ</source><year>2015</year><volume>5</volume><issue>1</issue><fpage>211</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1086/679726</pub-id><pub-id pub-id-type="pmid">25992284</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rather</surname><given-names>PA</given-names></name><name><surname>Hussain</surname><given-names>M</given-names></name><name><surname>Bagdadi</surname><given-names>F</given-names></name></person-group><article-title>Localized cutaneous mucinosis associated with multiple myeloma: A rare presentation</article-title><source>Indian J Dermatol</source><year>2014</year><volume>59</volume><issue>4</issue><fpage>422</fpage><pub-id pub-id-type="doi">10.4103/0019-5154.135538</pub-id><pub-id pub-id-type="pmid">25071283</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truhan</surname><given-names>AP</given-names></name><name><surname>Roenigk</surname><given-names>HH</given-names><suffix>Jr</suffix></name></person-group><article-title>Lichen myxedematosus. An unusual case with rapid progression and possible internal involvement</article-title><source>Int J Dermatol</source><year>1987</year><volume>26</volume><issue>2</issue><fpage>91</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4362.1987.tb00530.x</pub-id><pub-id pub-id-type="pmid">3570589</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuldeep</surname><given-names>CM</given-names></name><name><surname>Mittal</surname><given-names>AK</given-names></name><name><surname>Gupta</surname><given-names>LK</given-names></name><name><surname>Paliwal</surname><given-names>VK</given-names></name><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Garg</surname><given-names>A</given-names></name></person-group><article-title>Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy</article-title><source>Indian J Dermatol Venereol Leprol</source><year>2005</year><volume>71</volume><issue>1</issue><fpage>44</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.4103/0378-6323.13787</pub-id><pub-id pub-id-type="pmid">16394362</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feasel</surname><given-names>AM</given-names></name><name><surname>Donato</surname><given-names>ML</given-names></name><name><surname>Duvic</surname><given-names>M</given-names></name></person-group><article-title>Complete remission of scleromyxedema following autologous stem cell transplantation</article-title><source>Arch Dermatol</source><year>2001</year><volume>137</volume><fpage>1071</fpage><pub-id pub-id-type="pmid">11493100</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ataergin</surname><given-names>S</given-names></name><name><surname>Arpaci</surname><given-names>F</given-names></name><name><surname>Demiriz</surname><given-names>M</given-names></name><name><surname>Ozet</surname><given-names>A</given-names></name></person-group><article-title>Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema</article-title><source>Am J Clin Dermatol</source><year>2008</year><volume>9</volume><issue>4</issue><fpage>271</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.2165/00128071-200809040-00008</pub-id><pub-id pub-id-type="pmid">18572979</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rayson</surname><given-names>D</given-names></name><name><surname>Lust</surname><given-names>JA</given-names></name><name><surname>Duncan</surname><given-names>A</given-names></name><name><surname>Su</surname><given-names>WP</given-names></name></person-group><article-title>Scleromyxedema: A complete response to prednisone</article-title><source>Mayo Clin Proc</source><year>1999</year><volume>74</volume><issue>5</issue><fpage>481</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1016/S0025-6196(11)65128-8</pub-id><pub-id pub-id-type="pmid">10319080</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>RC</given-names></name><name><surname>Franco</surname><given-names>RS</given-names></name><name><surname>Denton</surname><given-names>D</given-names></name><name><surname>Blaney</surname><given-names>DJ</given-names></name></person-group><article-title>Scleromyxedema</article-title><source>Arch Dermatol</source><year>1976</year><volume>112</volume><issue>1</issue><fpage>63</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1001/archderm.1976.01630250027008</pub-id><pub-id pub-id-type="pmid">813582</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>HC</given-names></name><name><surname>Shen</surname><given-names>JL</given-names></name></person-group><article-title>Scleromyxedema: an experience using treatment with systemic corticosteroid and review of the published work</article-title><source>J Dermatol</source><year>2006</year><volume>33</volume><issue>3</issue><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1111/j.1346-8138.2006.00047.x</pub-id><pub-id pub-id-type="pmid">16620228</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreuter</surname><given-names>A</given-names></name><name><surname>Altmeyer</surname><given-names>P</given-names></name></person-group><article-title>High-dose dexamethasone in scleromyxedema: report of 2 additional cases</article-title><source>J Am Acad Dermatol</source><year>2005</year><volume>53</volume><issue>4</issue><fpage>739</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2005.04.012</pub-id><pub-id pub-id-type="pmid">16198811</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horn</surname><given-names>KB</given-names></name><name><surname>Horn</surname><given-names>MA</given-names></name><name><surname>Swan</surname><given-names>J</given-names></name><name><surname>Singhal</surname><given-names>S</given-names></name><name><surname>Guitart</surname><given-names>J</given-names></name></person-group><article-title>A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema</article-title><source>J Am Acad Dermatol</source><year>2004</year><volume>51</volume><issue>2 Suppl</issue><fpage>S120</fpage><lpage>S123</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2004.03.023</pub-id><pub-id pub-id-type="pmid">15280830</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacy</surname><given-names>MQ</given-names></name><name><surname>Hogan</surname><given-names>WJ</given-names></name><name><surname>Gertz</surname><given-names>MA</given-names></name><name><surname>Dispenzieri</surname><given-names>A</given-names></name><name><surname>Rajkumar</surname><given-names>SV</given-names></name><name><surname>Hayman</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation</article-title><source>Arch Dermatol</source><year>2005</year><volume>141</volume><issue>10</issue><fpage>1277</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1001/archderm.141.10.1277</pub-id><pub-id pub-id-type="pmid">16230566</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacFarlane</surname><given-names>AW</given-names></name><name><surname>Davenport</surname><given-names>A</given-names></name><name><surname>Verbov</surname><given-names>JL</given-names></name><name><surname>Goldsmith</surname><given-names>HJ</given-names></name></person-group><article-title>Scleromyxoedema—successful treatment with plasma exchange and immunosuppression</article-title><source>Br J Dermatol</source><year>1987</year><volume>117</volume><fpage>653</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1987.tb07499.x</pub-id><pub-id pub-id-type="pmid">3689684</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keong</surname><given-names>CH</given-names></name><name><surname>Asaka</surname><given-names>Y</given-names></name><name><surname>Fukuro</surname><given-names>S</given-names></name><name><surname>Miyamoto</surname><given-names>C</given-names></name><name><surname>Katsumata</surname><given-names>M</given-names></name><name><surname>Iino</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Successful treatment of scleromyxedema with plasmapheresis and immunosuppression</article-title><source>J Am Acad Dermatol</source><year>1990</year><volume>22</volume><issue>5 Pt 1</issue><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/S0190-9622(08)81176-0</pub-id><pub-id pub-id-type="pmid">2347969</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>TG</given-names></name><name><surname>Crawford</surname><given-names>JN</given-names></name><name><surname>Rogers</surname><given-names>CC</given-names></name></person-group><article-title>Successful management of lichen myxedematosus</article-title><source>Rep Case Arch Dermatol</source><year>1976</year><volume>112</volume><issue>1</issue><fpage>67</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1001/archderm.1976.01630250031009</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris-Jones</surname><given-names>R</given-names></name><name><surname>Staughton</surname><given-names>RC</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Sheridan</surname><given-names>DJ</given-names></name><name><surname>Rajappan</surname><given-names>K</given-names></name><name><surname>Leonard</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Lichen myxoedematosus with associated cardiac abnormalities</article-title><source>Br J Dermatol</source><year>2001</year><volume>144</volume><issue>3</issue><fpage>594</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04091.x</pub-id><pub-id pub-id-type="pmid">11260022</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidier</surname><given-names>M</given-names></name><name><surname>Zschoche</surname><given-names>C</given-names></name><name><surname>Gholam</surname><given-names>P</given-names></name><name><surname>Enk</surname><given-names>AH</given-names></name><name><surname>Hadaschik</surname><given-names>EN</given-names></name></person-group><article-title>Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes</article-title><source>Acta Derm Venereol</source><year>2012</year><volume>92</volume><issue>4</issue><fpage>408</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.2340/00015555-1299</pub-id><pub-id pub-id-type="pmid">22278389</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galiè</surname><given-names>N</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Vachiery</surname><given-names>JL</given-names></name><name><surname>Gibbs</surname><given-names>S</given-names></name><name><surname>Lang</surname><given-names>I</given-names></name><name><surname>Torbicki</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)</article-title><source>Eur Respir J</source><year>2015</year><volume>46</volume><issue>4</issue><fpage>1855</fpage><lpage>1856</lpage><pub-id pub-id-type="doi">10.1183/13993003.01032-2015</pub-id><pub-id pub-id-type="pmid">26621899</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marvin</surname><given-names>KS</given-names></name><name><surname>Spellberg</surname><given-names>RD</given-names></name></person-group><article-title>Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia</article-title><source>Chest</source><year>1993</year><volume>103</volume><issue>2</issue><fpage>642</fpage><lpage>644</lpage><pub-id pub-id-type="doi">10.1378/chest.103.2.642</pub-id><pub-id pub-id-type="pmid">8432180</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nand</surname><given-names>S</given-names></name><name><surname>Orfei</surname><given-names>E</given-names></name></person-group><article-title>Pulmonary hypertension in polycythemia vera</article-title><source>Am J Hematol</source><year>1994</year><volume>47</volume><issue>3</issue><fpage>242</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1002/ajh.2830470320</pub-id><pub-id pub-id-type="pmid">7942794</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossoff</surname><given-names>LJ</given-names></name><name><surname>Genovese</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>M</given-names></name><name><surname>Dantzker</surname><given-names>DR</given-names></name></person-group><article-title>Primary pulmonary hypertension in a patient with CD8/T-cell large granulocyte leukemia: amelioration by cladribine therapy</article-title><source>Chest</source><year>1997</year><volume>112</volume><issue>2</issue><fpage>551</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1378/chest.112.2.551</pub-id><pub-id pub-id-type="pmid">9266900</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Manero</surname><given-names>G</given-names></name><name><surname>Schuster</surname><given-names>SJ</given-names></name><name><surname>Patrick</surname><given-names>H</given-names></name><name><surname>Martinez</surname><given-names>J</given-names></name></person-group><article-title>Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases</article-title><source>Am J Hematol</source><year>1999</year><volume>60</volume><issue>2</issue><fpage>130</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-8652(199902)60:2<130::AID-AJH8>3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">9929105</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dingli</surname><given-names>D</given-names></name><name><surname>Utz</surname><given-names>JP</given-names></name><name><surname>Krowka</surname><given-names>MJ</given-names></name><name><surname>Oberg</surname><given-names>AL</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>Unexplained pulmonary hypertension in chronic myeloproliferative disorders</article-title><source>Chest</source><year>2001</year><volume>120</volume><issue>3</issue><fpage>801</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1378/chest.120.3.801</pub-id><pub-id pub-id-type="pmid">11555513</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steensma</surname><given-names>DP</given-names></name><name><surname>Hook</surname><given-names>CC</given-names></name><name><surname>Stafford</surname><given-names>SL</given-names></name><name><surname>Tefferi</surname><given-names>A</given-names></name></person-group><article-title>Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia</article-title><source>Br J Haematol</source><year>2002</year><volume>118</volume><issue>3</issue><fpage>813</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2141.2002.03695.x</pub-id><pub-id pub-id-type="pmid">12181050</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popat</surname><given-names>U</given-names></name><name><surname>Frost</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>May</surname><given-names>R</given-names></name><name><surname>Bag</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>New onset of myelofibrosis in association with pulmonary arterial hypertension</article-title><source>Ann Intern Med</source><year>2005</year><volume>143</volume><issue>6</issue><fpage>466</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-143-6-200509200-00017</pub-id><pub-id pub-id-type="pmid">16172450</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostagno</surname><given-names>C</given-names></name><name><surname>Ciolli</surname><given-names>S</given-names></name></person-group><article-title>Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma</article-title><source>Ann Hematol</source><year>2006</year><volume>85</volume><issue>9</issue><fpage>627</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1007/s00277-006-0124-2</pub-id><pub-id pub-id-type="pmid">16705455</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortelezzi</surname><given-names>A</given-names></name><name><surname>Gritti</surname><given-names>G</given-names></name><name><surname>Del Papa</surname><given-names>N</given-names></name><name><surname>Pasquini</surname><given-names>MC</given-names></name><name><surname>Calori</surname><given-names>R</given-names></name><name><surname>Gianelli</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status</article-title><source>Leukemia.</source><year>2008</year><volume>22</volume><issue>3</issue><fpage>646</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2404943</pub-id><pub-id pub-id-type="pmid">17851555</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willems</surname><given-names>E</given-names></name><name><surname>Canivet</surname><given-names>JL</given-names></name><name><surname>Ghaye</surname><given-names>B</given-names></name><name><surname>de Leval</surname><given-names>L</given-names></name><name><surname>Radermecker</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Pulmonary veno-occlusive disease in myeloproliferative disorder</article-title><source>Eur Respir J</source><year>2009</year><volume>33</volume><issue>1</issue><fpage>213</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1183/09031936.00157707</pub-id><pub-id pub-id-type="pmid">19118232</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adir</surname><given-names>Y</given-names></name><name><surname>Elia</surname><given-names>D</given-names></name><name><surname>Harari</surname><given-names>S</given-names></name></person-group><article-title>Pulmonary hypertension in patients with chronic myeloproliferative disorders</article-title><source>Eur Respir Rev</source><year>2015</year><volume>24</volume><issue>137</issue><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1183/16000617.0041-2015</pub-id><pub-id pub-id-type="pmid">26324801</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>U</given-names></name><name><surname>Mark</surname><given-names>TM</given-names></name><name><surname>Niesvizky</surname><given-names>R</given-names></name><name><surname>Sobol</surname><given-names>I</given-names></name></person-group><article-title>Pulmonary hypertension complicating multiple myeloma</article-title><source>Pulm Circ.</source><year>2015</year><volume>5</volume><issue>3</issue><fpage>590</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1086/682430</pub-id><pub-id pub-id-type="pmid">26401262</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roach</surname><given-names>EC</given-names></name><name><surname>Park</surname><given-names>MM</given-names></name><name><surname>Tang</surname><given-names>WH</given-names></name><name><surname>Thomas</surname><given-names>JD</given-names></name><name><surname>Asosingh</surname><given-names>K</given-names></name><name><surname>Kalaycio</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms</article-title><source>J Heart Lung Transplant</source><year>2015</year><volume>34</volume><issue>3</issue><fpage>390</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2014.09.009</pub-id><pub-id pub-id-type="pmid">25638299</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattar</surname><given-names>Mervat M.</given-names></name><name><surname>Morad</surname><given-names>Mohammed Abdel Kader</given-names></name><name><surname>El Husseiny</surname><given-names>Noha M.</given-names></name><name><surname>Ali</surname><given-names>Noha H.</given-names></name><name><surname>El Demerdash</surname><given-names>Doaa M.</given-names></name></person-group><article-title>Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience</article-title><source>Annals of Hematology</source><year>2016</year><volume>95</volume><issue>10</issue><fpage>1611</fpage><lpage>1616</lpage><pub-id pub-id-type="doi">10.1007/s00277-016-2765-0</pub-id><pub-id pub-id-type="pmid">27468853</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montani</surname><given-names>D</given-names></name><name><surname>Achouh</surname><given-names>L</given-names></name><name><surname>Marcelin</surname><given-names>AG</given-names></name><name><surname>Viard</surname><given-names>JP</given-names></name><name><surname>Hermine</surname><given-names>O</given-names></name><name><surname>Canioni</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease</article-title><source>Eur Respir J</source><year>2005</year><volume>26</volume><issue>5</issue><fpage>969</fpage><lpage>972</lpage><pub-id pub-id-type="doi">10.1183/09031936.05.00133904</pub-id><pub-id pub-id-type="pmid">16264059</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taytawat</surname><given-names>P</given-names></name></person-group><article-title>Reversible pulmonary hypertension and isolated right heart failure associated with multiple myeloma</article-title><source>Chest</source><year>2013</year><volume>144</volume><issue>4_MeetingAbstracts</issue><fpage>155A</fpage><pub-id pub-id-type="doi">10.1378/chest.1702447</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>S</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name><name><surname>Shiotani</surname><given-names>C</given-names></name><name><surname>Kurihara</surname><given-names>T</given-names></name><name><surname>Nishikawa</surname><given-names>A</given-names></name><name><surname>Okamoto</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension</article-title><source>Intern Med</source><year>2014</year><volume>53</volume><issue>11</issue><fpage>1171</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.53.1672</pub-id><pub-id pub-id-type="pmid">24881743</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warsame</surname><given-names>R</given-names></name><name><surname>Kohut</surname><given-names>IE</given-names></name><name><surname>Dispenzieri</surname><given-names>A</given-names></name></person-group><article-title>Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS</article-title><source>Eur J Haematol</source><year>2012</year><volume>88</volume><issue>6</issue><fpage>549</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2012.01780.x</pub-id><pub-id pub-id-type="pmid">22416898</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adam</surname><given-names>Z</given-names></name><name><surname>Krejčí</surname><given-names>M</given-names></name><name><surname>Pour</surname><given-names>L</given-names></name><name><surname>Feit</surname><given-names>J</given-names></name><name><surname>Büchler</surname><given-names>T</given-names></name><name><surname>Hájek</surname><given-names>R</given-names></name></person-group><article-title>IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen</article-title><source>Wien Klin Wochenschr</source><year>2010</year><volume>122</volume><issue>9–10</issue><fpage>311</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1007/s00508-010-1361-x</pub-id><pub-id pub-id-type="pmid">20559888</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Chinen K, Fujioka Y. Severe pulmonary hypertension caused by smoldering plasma cell myeloma: an autopsy case of POEMS syndrome. Case Rep Med. 2012:836893.</mixed-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>A</given-names></name><name><surname>Farr</surname><given-names>G</given-names></name><name><surname>Grinnan</surname><given-names>D</given-names></name></person-group><article-title>Improvement in pulmonary arterial hypertension associated with Castleman's disease after treatment with ambrisentan and rituximab</article-title><source>Chest</source><year>2015</year><volume>148</volume><issue>4 Supp</issue><fpage>994A</fpage><pub-id pub-id-type="doi">10.1378/chest.2263218</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyakoshi</surname><given-names>S</given-names></name><name><surname>Kami</surname><given-names>M</given-names></name><name><surname>Yuji</surname><given-names>K</given-names></name><name><surname>Matsumura</surname><given-names>T</given-names></name><name><surname>Takatoku</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma</article-title><source>Blood</source><year>2006</year><volume>107</volume><issue>9</issue><fpage>3492</fpage><lpage>3494</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-11-4541</pub-id><pub-id pub-id-type="pmid">16410442</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyer</surname><given-names>JE</given-names></name><name><surname>Batra</surname><given-names>RB</given-names></name><name><surname>Ascensao</surname><given-names>JL</given-names></name><name><surname>Schechter</surname><given-names>GP</given-names></name></person-group><article-title>Severe pulmonary complication after bortezomib treatment for multiple myeloma</article-title><source>Blood</source><year>2006</year><volume>108</volume><issue>3</issue><fpage>1113</fpage><pub-id pub-id-type="doi">10.1182/blood-2006-03-011494</pub-id><pub-id pub-id-type="pmid">16861361</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>A</given-names></name><name><surname>Ohyashiki</surname><given-names>K</given-names></name><name><surname>Oshimi</surname><given-names>K</given-names></name><name><surname>Usui</surname><given-names>N</given-names></name><name><surname>Hotta</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by Bortezomib" joint committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology</article-title><source>Int J Hematol</source><year>2006</year><volume>84</volume><issue>5</issue><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1532/IJH97.06142</pub-id><pub-id pub-id-type="pmid">17189220</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohri</surname><given-names>A</given-names></name><name><surname>Arena</surname><given-names>FP</given-names></name></person-group><article-title>Severe pulmonary complications in African-American patient after bortezomib therapy</article-title><source>Am J Ther</source><year>2006</year><volume>13</volume><issue>6</issue><fpage>553</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1097/01.mjt.0000245224.20913.0d</pub-id><pub-id pub-id-type="pmid">17122539</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>E</given-names></name><name><surname>Filshie</surname><given-names>R</given-names></name><name><surname>Wei</surname><given-names>A</given-names></name></person-group><article-title>Development of fatal bortezomib induced acute lung injury despite concurrent therapy with high-dose dexamethasone</article-title><source>Leuk Lymphoma</source><year>2007</year><volume>48</volume><issue>1</issue><fpage>212</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1080/10428190600988010</pub-id><pub-id pub-id-type="pmid">17325874</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duek</surname><given-names>A</given-names></name><name><surname>Feldberg</surname><given-names>E</given-names></name><name><surname>Haran</surname><given-names>M</given-names></name><name><surname>Berrebi</surname><given-names>A</given-names></name></person-group><article-title>Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug</article-title><source>Am J Hematol</source><year>2007</year><volume>82</volume><issue>6</issue><fpage>502</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/ajh.20891</pub-id><pub-id pub-id-type="pmid">17301973</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitini</surname><given-names>V</given-names></name><name><surname>Arrigo</surname><given-names>C</given-names></name><name><surname>Altavilla</surname><given-names>G</given-names></name><name><surname>Naro</surname><given-names>C</given-names></name></person-group><article-title>Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?</article-title><source>Leuk Res</source><year>2007</year><volume>31</volume><issue>7</issue><fpage>1027</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1016/j.leukres.2006.09.015</pub-id><pub-id pub-id-type="pmid">17134751</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zappasodi</surname><given-names>P</given-names></name><name><surname>Dore</surname><given-names>R</given-names></name><name><surname>Castagnola</surname><given-names>C</given-names></name><name><surname>Astori</surname><given-names>C</given-names></name><name><surname>Varettoni</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><issue>22</issue><fpage>3380</fpage><lpage>3381</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.10.0164</pub-id><pub-id pub-id-type="pmid">17664489</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafaras</surname><given-names>C</given-names></name><name><surname>Mandala</surname><given-names>E</given-names></name><name><surname>Verrou</surname><given-names>E</given-names></name><name><surname>Platogiannis</surname><given-names>D</given-names></name><name><surname>Barbetakis</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><issue>10</issue><fpage>1765</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn287</pub-id><pub-id pub-id-type="pmid">18480066</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghose</surname><given-names>A</given-names></name><name><surname>Tariq</surname><given-names>Z</given-names></name><name><surname>Taj</surname><given-names>A</given-names></name><name><surname>Chaudhary</surname><given-names>R</given-names></name></person-group><article-title>Acute dyspnea from treatment of AL amyloidosis with bortezomib</article-title><source>Am J Ther</source><year>2011</year><volume>18</volume><issue>4</issue><fpage>e123</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1097/MJT.0b013e3181cea0ef</pub-id><pub-id pub-id-type="pmid">20335791</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montani</surname><given-names>D</given-names></name><name><surname>Bergot</surname><given-names>E</given-names></name><name><surname>Günther</surname><given-names>S</given-names></name><name><surname>Savale</surname><given-names>L</given-names></name><name><surname>Bergeron</surname><given-names>A</given-names></name><name><surname>Bourdin</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Pulmonary arterial hypertension in patients treated by dasatinib</article-title><source>Circ</source><year>2012</year><volume>125</volume><issue>17</issue><fpage>2128</fpage><lpage>2137</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.079921</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akosman</surname><given-names>C</given-names></name><name><surname>Ordu</surname><given-names>C</given-names></name><name><surname>Eroglu</surname><given-names>E</given-names></name><name><surname>Oyan</surname><given-names>B</given-names></name></person-group><article-title>Development of acute pulmonary hypertension after bortezomib treatment in a patient with multiple myeloma: a case report and the review of the literature</article-title><source>Am J Ther</source><year>2015</year><volume>22</volume><issue>3</issue><fpage>e88</fpage><lpage>e92</lpage><pub-id pub-id-type="doi">10.1097/01.mjt.0000433941.91996.5f</pub-id><pub-id pub-id-type="pmid">24100255</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugita</surname><given-names>Y</given-names></name><name><surname>Ohwada</surname><given-names>C</given-names></name><name><surname>Nagao</surname><given-names>Y</given-names></name><name><surname>Kawajiri</surname><given-names>C</given-names></name><name><surname>Shimizu</surname><given-names>R</given-names></name><name><surname>Togasaki</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Early-onset severe diffuse alveolar hemorrhage after bortezomib administration suggestive of pulmonary involvement of myeloma cells</article-title><source>J Clin Exp Hematop</source><year>2015</year><volume>55</volume><issue>3</issue><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.3960/jslrt.55.163</pub-id><pub-id pub-id-type="pmid">26763365</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranchoux</surname><given-names>B</given-names></name><name><surname>Günther</surname><given-names>S</given-names></name><name><surname>Quarck</surname><given-names>R</given-names></name><name><surname>Chaumais</surname><given-names>MC</given-names></name><name><surname>Dorfmüller</surname><given-names>P</given-names></name><name><surname>Antigny</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Chemotherapy-induced pulmonary hypertension: role of alkylating agents</article-title><source>Am J Pathol</source><year>2015</year><volume>185</volume><issue>2</issue><fpage>356</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2014.10.021</pub-id><pub-id pub-id-type="pmid">25497573</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumitrescu</surname><given-names>D</given-names></name><name><surname>Seck</surname><given-names>C</given-names></name><name><surname>ten Freyhaus</surname><given-names>H</given-names></name><name><surname>Gerhardt</surname><given-names>F</given-names></name><name><surname>Erdmann</surname><given-names>E</given-names></name><name><surname>Rosenkranz</surname><given-names>S</given-names></name></person-group><article-title>Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia</article-title><source>Eur Respir J</source><year>2011</year><volume>38</volume><issue>1</issue><fpage>218</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1183/09031936.00154210</pub-id><pub-id pub-id-type="pmid">21719499</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Meka S, Otoupalova E, Patel V, Cichewiz A, Dalal B. Rituximab: Friend or foe for PAH? 2016 Oct;150(4 Supp):1215A.</mixed-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montrone</surname><given-names>D</given-names></name><name><surname>Correale</surname><given-names>M</given-names></name><name><surname>Franzese</surname><given-names>MG</given-names></name><name><surname>Ieva</surname><given-names>R</given-names></name><name><surname>Di Biase</surname><given-names>M</given-names></name><name><surname>Capalbo</surname><given-names>SF</given-names></name></person-group><article-title>Pulmonary arterial hypertension in a chronic lymphocytic leukemia patient in treatment with rituximab</article-title><source>J Cardiovasc Med (Hagerstown)</source><year>2015</year><volume>16</volume><issue>Suppl 1</issue><fpage>S65</fpage><pub-id pub-id-type="doi">10.2459/JCM.0b013e3283621adf</pub-id><pub-id pub-id-type="pmid">25643063</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekerkoetter</surname><given-names>E</given-names></name><name><surname>Sung</surname><given-names>YK</given-names></name><name><surname>Sudheendra</surname><given-names>D</given-names></name><name><surname>Bill</surname><given-names>M</given-names></name><name><surname>Aldred</surname><given-names>MA</given-names></name><name><surname>van de Veerdonk</surname><given-names>MC</given-names></name><etal></etal></person-group><article-title>Low-dose FK506 (Tacrolimus) in end-stage pulmonary arterial hypertension</article-title><source>Am J Respir Crit Care Med</source><year>2015</year><volume>192</volume><issue>2</issue><fpage>254</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1164/rccm.201411-2061LE</pub-id><pub-id pub-id-type="pmid">26177174</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiekerkoetter</surname><given-names>E</given-names></name><name><surname>Tian</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Hopper</surname><given-names>RK</given-names></name><name><surname>Sudheendra</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>CG</given-names></name><etal></etal></person-group><article-title>FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><issue>8</issue><fpage>3600</fpage><lpage>3613</lpage><pub-id pub-id-type="doi">10.1172/JCI65592</pub-id><pub-id pub-id-type="pmid">23867624</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schermuly</surname><given-names>RT</given-names></name><name><surname>Dony</surname><given-names>E</given-names></name><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Pullamsetti</surname><given-names>S</given-names></name><name><surname>Savai</surname><given-names>R</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Reversal of experimental pulmonary hypertension by PDGF inhibition</article-title><source>J Clin Invest</source><year>2005</year><volume>115</volume><issue>10</issue><fpage>2811</fpage><lpage>2821</lpage><pub-id pub-id-type="doi">10.1172/JCI24838</pub-id><pub-id pub-id-type="pmid">16200212</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamata</surname><given-names>Y</given-names></name><name><surname>Nara</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Masuyama</surname><given-names>JI</given-names></name><name><surname>Minota</surname><given-names>S</given-names></name><name><surname>Yoshio</surname><given-names>T</given-names></name></person-group><article-title>Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension</article-title><source>Ann Rheum Dis</source><year>2005</year><volume>64</volume><issue>8</issue><fpage>1236</fpage><lpage>1237</lpage><pub-id pub-id-type="doi">10.1136/ard.2004.029074</pub-id><pub-id pub-id-type="pmid">16014687</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbaum</surname><given-names>L</given-names></name><name><surname>Hennigs</surname><given-names>JK</given-names></name><name><surname>Baumann</surname><given-names>HJ</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Olschewski</surname><given-names>H</given-names></name><name><surname>Klose</surname><given-names>H</given-names></name></person-group><article-title>Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy</article-title><source>Eur Respir J</source><year>2014</year><volume>43</volume><issue>5</issue><fpage>1513</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1183/09031936.00185713</pub-id><pub-id pub-id-type="pmid">24789952</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferri</surname><given-names>C</given-names></name><name><surname>Emdin</surname><given-names>M</given-names></name><name><surname>Storino</surname><given-names>FA</given-names></name><name><surname>Giuggioli</surname><given-names>D</given-names></name><name><surname>Longombardo</surname><given-names>G</given-names></name><name><surname>Greco</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Isolated pulmonary hypertension in diffuse cutaneous systemic sclerosis successfully treated with long-term plasma exchange</article-title><source>Scand J Rheumatol</source><year>2000</year><volume>29</volume><issue>3</issue><fpage>198</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1080/030097400750002120</pub-id><pub-id pub-id-type="pmid">10898077</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meloche</surname><given-names>J</given-names></name><name><surname>Renard</surname><given-names>S</given-names></name><name><surname>Provencher</surname><given-names>S</given-names></name><name><surname>Bonnet</surname><given-names>S</given-names></name></person-group><article-title>Anti-inflammatory and immunosuppressive agents in PAH</article-title><source>Handb Exp Pharmacol</source><year>2013</year><volume>218</volume><fpage>437</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1007/978-3-662-45805-1_18</pub-id><pub-id pub-id-type="pmid">24092351</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawa</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Mizoguchi</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Fujio</surname><given-names>H</given-names></name><name><surname>Kusano</surname><given-names>KF</given-names></name><etal></etal></person-group><article-title>Prednisolone ameliorates idiopathic pulmonary arterial hypertension</article-title><source>Am J Respir Crit Care Med</source><year>2011</year><volume>183</volume><issue>1</issue><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.183.1.139</pub-id><pub-id pub-id-type="pmid">21193794</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellotto</surname><given-names>F</given-names></name><name><surname>Chiavacci</surname><given-names>P</given-names></name><name><surname>Laveder</surname><given-names>F</given-names></name><name><surname>Angelini</surname><given-names>A</given-names></name><name><surname>Thiene</surname><given-names>G</given-names></name><name><surname>Marcolongo</surname><given-names>R</given-names></name></person-group><article-title>Effective immunosuppressive therapy in a patient with primary pulmonary hypertension</article-title><source>Thorax</source><year>1999</year><volume>54</volume><issue>4</issue><fpage>372</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1136/thx.54.4.372</pub-id><pub-id pub-id-type="pmid">10092701</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aggarwal</surname><given-names>M</given-names></name></person-group><article-title>Grady RM1. Glucocorticoids for treating paediatric pulmonary hypertension: a novel use for a common medication</article-title><source>Cardiol Young</source><year>2017</year><volume>27</volume><issue>7</issue><fpage>1410</fpage><lpage>1412</lpage><pub-id pub-id-type="doi">10.1017/S1047951117000464</pub-id><pub-id pub-id-type="pmid">28506331</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Haritha J, Syed H, Nandan A, Grinnan D. Report shows rituximab may help treat MCTD-associated PAH. Rheumatologist. 2018 April 26.</mixed-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennigan</surname><given-names>S</given-names></name><name><surname>Channick</surname><given-names>RN</given-names></name><name><surname>Silverman</surname><given-names>GJ</given-names></name></person-group><article-title>Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report</article-title><source>Lupus</source><year>2008</year><volume>17</volume><issue>8</issue><fpage>754</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1177/0961203307087610</pub-id><pub-id pub-id-type="pmid">18625655</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padilla-Ibarra</surname><given-names>J</given-names></name><name><surname>Sanchez-Ortiz</surname><given-names>A</given-names></name><name><surname>Sandoval-Castro</surname><given-names>C</given-names></name><name><surname>Ramos-Remus</surname><given-names>C</given-names></name></person-group><article-title>Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease</article-title><source>Clin Exp Rheumatol</source><year>2013</year><volume>31</volume><issue>4</issue><fpage>657</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">23622421</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dandel</surname><given-names>M</given-names></name><name><surname>Wallukat</surname><given-names>G</given-names></name><name><surname>Englert</surname><given-names>A</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name></person-group><article-title>Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension</article-title><source>Atheroscler Suppl</source><year>2013</year><volume>14</volume><issue>1</issue><fpage>203</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosissup.2012.10.029</pub-id><pub-id pub-id-type="pmid">23357166</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagel</surname><given-names>C</given-names></name><name><surname>Ewert</surname><given-names>R</given-names></name><name><surname>Egenlauf</surname><given-names>B</given-names></name><name><surname>Lehmkuhl</surname><given-names>HB</given-names></name><name><surname>Rosenkranz</surname><given-names>S</given-names></name><name><surname>Benjamin</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with severe idiopathic pulmonary arterial hypertension</article-title><source>Respir</source><year>2017</year><volume>94</volume><issue>3</issue><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1159/000478744</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>XY</given-names></name><name><surname>Li</surname><given-names>YT</given-names></name><name><surname>Hao</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>YP</given-names></name><etal></etal></person-group><article-title>Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension</article-title><source>Mol Biol Rep</source><year>2011</year><volume>38</volume><issue>5</issue><fpage>3277</fpage><lpage>3284</lpage><pub-id pub-id-type="doi">10.1007/s11033-010-0390-x</pub-id><pub-id pub-id-type="pmid">21431360</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>LC</given-names></name><name><surname>Montani</surname><given-names>D</given-names></name><name><surname>Tcherakian</surname><given-names>C</given-names></name><name><surname>Dorfmüller</surname><given-names>P</given-names></name><name><surname>Souza</surname><given-names>R</given-names></name><name><surname>Gambaryan</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats</article-title><source>Eur Respir J</source><year>2011</year><volume>37</volume><issue>4</issue><fpage>813</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1183/09031936.00028310</pub-id><pub-id pub-id-type="pmid">20693255</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Huh</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Park</surname><given-names>MK</given-names></name><etal></etal></person-group><article-title>Bortezomib alleviates experimental pulmonary arterial hypertension</article-title><source>Am J Respir Cell Mol Biol</source><year>2012</year><volume>47</volume><issue>5</issue><fpage>698</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2011-0331OC</pub-id><pub-id pub-id-type="pmid">22842494</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Luan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>ZH</given-names></name><etal></etal></person-group><article-title>Proteasome inhibitor PS-341 attenuates flow-induced pulmonary arterial hypertension</article-title><source>Clin Exp Med</source><year>2014</year><volume>14</volume><issue>3</issue><fpage>321</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1007/s10238-013-0244-7</pub-id><pub-id pub-id-type="pmid">23771811</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>ZS</given-names></name><name><surname>Luan</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>XB</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>The effect of PS-341 on pulmonary vascular remodeling in high blood flow-induced pulmonary hypertension</article-title><source>Int J Mol Med</source><year>2014</year><volume>33</volume><issue>1</issue><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1562</pub-id><pub-id pub-id-type="pmid">24270576</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Jun</given-names></name><name><surname>Lu</surname><given-names>Wenju</given-names></name><name><surname>Chen</surname><given-names>Yuqin</given-names></name><name><surname>Jiang</surname><given-names>Qian</given-names></name><name><surname>Yang</surname><given-names>Kai</given-names></name><name><surname>Li</surname><given-names>Meichan</given-names></name><name><surname>Wang</surname><given-names>Ziyi</given-names></name><name><surname>Duan</surname><given-names>Xin</given-names></name><name><surname>Xu</surname><given-names>Lei</given-names></name><name><surname>Tang</surname><given-names>Haiyang</given-names></name><name><surname>Sun</surname><given-names>Dejun</given-names></name><name><surname>Wang</surname><given-names>Jian</given-names></name></person-group><article-title>Bortezomib alleviates experimental pulmonary hypertension by regulating intracellular calcium homeostasis in PASMCs</article-title><source>American Journal of Physiology-Cell Physiology</source><year>2016</year><volume>311</volume><issue>3</issue><fpage>C482</fpage><lpage>C497</lpage><pub-id pub-id-type="doi">10.1152/ajpcell.00324.2015</pub-id><pub-id pub-id-type="pmid">27413173</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal></etal></person-group><article-title>Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial remodeling</article-title><source>Life Sci</source><year>2017</year><volume>173</volume><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2017.02.007</pub-id><pub-id pub-id-type="pmid">28212825</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ibrahim</surname><given-names>YF</given-names></name><name><surname>Wong</surname><given-names>CM</given-names></name><name><surname>Pavlickova</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Trasar</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing</article-title><source>J Am Heart Assoc</source><year>2014</year><volume>3</volume><issue>1</issue><fpage>e000520</fpage><pub-id pub-id-type="doi">10.1161/JAHA.113.000520</pub-id><pub-id pub-id-type="pmid">24572252</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rongioletti</surname><given-names>F</given-names></name><name><surname>Cattarini</surname><given-names>G</given-names></name><name><surname>Sottofattori</surname><given-names>E</given-names></name><name><surname>Rebora</surname><given-names>A</given-names></name></person-group><article-title>Granulomatous reaction after intradermal injections of hyaluronic acid gel</article-title><source>Arch Dermatol</source><year>2003</year><volume>139</volume><issue>6</issue><fpage>815</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1001/archderm.139.6.815</pub-id><pub-id pub-id-type="pmid">12810524</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>LC</given-names></name><name><surname>Wort</surname><given-names>SJ</given-names></name><name><surname>Perros</surname><given-names>F</given-names></name><name><surname>Dorfmüller</surname><given-names>P</given-names></name><name><surname>Huertas</surname><given-names>A</given-names></name><name><surname>Montani</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Inflammation in pulmonary arterial hypertension</article-title><source>Chest.</source><year>2012</year><volume>141</volume><issue>1</issue><fpage>210</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1378/chest.11-0793</pub-id><pub-id pub-id-type="pmid">22215829</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>JX</given-names></name><name><surname>Rubin</surname><given-names>LJ</given-names></name></person-group><article-title>Pathogenesis of pulmonary arterial hypertension: the need for multiple hits</article-title><source>Circ</source><year>2005</year><volume>111</volume><issue>5</issue><fpage>534</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000156326.48823.55</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boucherat</surname><given-names>O</given-names></name><name><surname>Vitry</surname><given-names>G</given-names></name><name><surname>Trinh</surname><given-names>I</given-names></name><name><surname>Paulin</surname><given-names>R</given-names></name><name><surname>Provencher</surname><given-names>S</given-names></name><name><surname>Bonnet</surname><given-names>S</given-names></name></person-group><article-title>The cancer theory of pulmonary arterial hypertension</article-title><source>Pulm Circ</source><year>2017</year><volume>7</volume><issue>2</issue><fpage>285</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1177/2045893217701438</pub-id><pub-id pub-id-type="pmid">28597757</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamby</surname><given-names>MC</given-names></name><name><surname>Chanseaud</surname><given-names>Y</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Fermanian</surname><given-names>J</given-names></name><name><surname>Guilpain</surname><given-names>P</given-names></name><name><surname>Garcia-de-la-Peña-Lefebvre</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension</article-title><source>Thorax</source><year>2005</year><volume>60</volume><issue>9</issue><fpage>765</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1136/thx.2004.029082</pub-id><pub-id pub-id-type="pmid">16135682</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamby</surname><given-names>MC</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Guilpain</surname><given-names>P</given-names></name><name><surname>Servettaz</surname><given-names>A</given-names></name><name><surname>Dupin</surname><given-names>N</given-names></name><name><surname>Christner</surname><given-names>JJ</given-names></name><etal></etal></person-group><article-title>Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension</article-title><source>Eur Respir J</source><year>2006</year><volume>28</volume><issue>4</issue><fpage>799</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1183/09031936.06.00152705</pub-id><pub-id pub-id-type="pmid">16774952</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guignabert</surname><given-names>C</given-names></name><name><surname>Tu</surname><given-names>L</given-names></name><name><surname>Le Hiress</surname><given-names>M</given-names></name><name><surname>Ricard</surname><given-names>N</given-names></name><name><surname>Sattler</surname><given-names>C</given-names></name><name><surname>Seferian</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Pathogenesis of pulmonary arterial hypertension: lessons from cancer</article-title><source>Eur Respir Rev</source><year>2013</year><volume>22</volume><issue>130</issue><fpage>543</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1183/09059180.00007513</pub-id><pub-id pub-id-type="pmid">24293470</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacher</surname><given-names>E</given-names></name><name><surname>Graham</surname><given-names>BB</given-names></name><name><surname>Hunt</surname><given-names>JM</given-names></name><name><surname>Gandjeva</surname><given-names>A</given-names></name><name><surname>Groshong</surname><given-names>SD</given-names></name><name><surname>McLaughlin</surname><given-names>VV</given-names></name><etal></etal></person-group><article-title>Modern age pathology of pulmonary arterial hypertension</article-title><source>Am J Respir Crit Care Med</source><year>2012</year><volume>186</volume><issue>3</issue><fpage>261</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1164/rccm.201201-0164OC</pub-id><pub-id pub-id-type="pmid">22679007</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>N</given-names></name><name><surname>Tsutsui</surname><given-names>H</given-names></name><name><surname>Fukuyama</surname><given-names>K</given-names></name><name><surname>Hayashidani</surname><given-names>S</given-names></name><name><surname>Koike</surname><given-names>G</given-names></name><name><surname>Egashira</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity</article-title><source>Intern Med</source><year>2002</year><volume>41</volume><issue>2</issue><fpage>109</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.41.109</pub-id><pub-id pub-id-type="pmid">11868596</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukerjee</surname><given-names>D</given-names></name><name><surname>St George</surname><given-names>D</given-names></name><name><surname>Coleiro</surname><given-names>B</given-names></name><name><surname>Knight</surname><given-names>C</given-names></name><name><surname>Denton</surname><given-names>CP</given-names></name><name><surname>Davar</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach</article-title><source>Ann Rheum Dis</source><year>2003</year><volume>62</volume><issue>11</issue><fpage>1088</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1136/ard.62.11.1088</pub-id><pub-id pub-id-type="pmid">14583573</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordley</surname><given-names>JE</given-names></name><name><surname>Carey</surname><given-names>RA</given-names></name><etal></etal></person-group><article-title>Preliminary observations on the effect of adrenocorticotropic hormone in allergic diseases</article-title><source>Bull Johns Hopkins Hosp</source><year>1949</year><volume>85</volume><issue>5</issue><fpage>396</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">15392092</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Röllig</surname><given-names>C</given-names></name><name><surname>Knop</surname><given-names>S</given-names></name><name><surname>Bornhäuser</surname><given-names>M</given-names></name></person-group><article-title>Multiple myeloma</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9983</issue><fpage>2197</fpage><lpage>2208</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)60493-1</pub-id><pub-id pub-id-type="pmid">25540889</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiner</surname><given-names>GJ</given-names></name></person-group><article-title>Rituximab: mechanism of action</article-title><source>Semin Hematol</source><year>2010</year><volume>47</volume><issue>2</issue><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1053/j.seminhematol.2010.01.011</pub-id><pub-id pub-id-type="pmid">20350658</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>PG</given-names></name><name><surname>Weller</surname><given-names>E</given-names></name><name><surname>Lonial</surname><given-names>S</given-names></name><name><surname>Jakubowiak</surname><given-names>AJ</given-names></name><name><surname>Jagannath</surname><given-names>S</given-names></name><name><surname>Raje</surname><given-names>NS</given-names></name><etal></etal></person-group><article-title>Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma</article-title><source>Blood</source><year>2010</year><volume>116</volume><issue>5</issue><fpage>679</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-02-268862</pub-id><pub-id pub-id-type="pmid">20385792</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lub</surname><given-names>S</given-names></name><name><surname>Maes</surname><given-names>K</given-names></name><name><surname>Menu</surname><given-names>E</given-names></name><name><surname>De Bruyne</surname><given-names>E</given-names></name><name><surname>Vanderkerken</surname><given-names>K</given-names></name><name><surname>Van Valckenborgh</surname><given-names>E</given-names></name></person-group><article-title>Novel strategies to target the ubiquitin proteasome system in multiple myeloma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><issue>6</issue><fpage>6521</fpage><lpage>6537</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6658</pub-id><pub-id pub-id-type="pmid">26695547</pub-id></element-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000015 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000015 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6953266
|texte= Severe but reversible pulmonary hypertension in scleromyxedema and multiple myeloma: a case report
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:31918690" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |